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AN ENTREPRENEUR'S GUIDEBOOK 
Deloitte Haskins & Sells is an international accounting 
firm of more than 26,000 people, in 423 offices,  in 70 countries. 
We serve an almost endless variety of clients, private and public, 
around the world. 
This guidebook was prepared by our High Technology 
Industry Group. The Group comprises professionals in the areas 
of management consulting, tax, accounting and auditing, who 
have developed significant expertise in dealing with the particular 
problems high technology companies experience. A substantial 
portion of their time is devoted to serving clients in electronics, 
medical, high technology manufacturing, and related industries. 
The specialists in this Group stand ready to respond to 
any company's needs with a full range of integrated services 
which comprehend the many complexities and unique features 
of the high technology industry. 
Forming  R&D Partnerships  is the third guidebook in our 
Entrepreneur's Series. Response to the first  two guidebooks has 
been more than gratifying.  Raising  Venture  Capital  and Strategies 
for  Going Public  filled an informational need for entrepreneurs. 
We're confident that Forming  R&D Partnerships  will do 
the same. 
The High Technology Industry Group gratefully acknowl-
edges PRX-TECH Agency for its assistance in coordinating and 
producing Forming  R&D Partnerships. 
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EXECUTIVE 
SUMMARY 
One problem faced by all companies - start-ups as well as 
established ones - is how to finance the research and develop-
ment necessary to convert their ideas into successful products. 
Many companies have recently turned to R&D partnerships for 
this financing. 
Although R&D partnerships have been used since the 
mid-1970s they did not become popular until 1981. Until then, 
many investors were wary that the IRS would view such partner-
ships as elaborate financing/tax sheltering techniques rather 
than legitimate projects. But with the large offerings  by Storage 
Technology Corp. and Trilogy Limited in 1981, backed by 
reputable investment bankers, R&D partnerships came of age 
and are now acceptable financing vehicles for raising $50,000 or 
$50 million, for starting a new company or for funding a mature 
one. 
The market for R&D partnerships is just starting to be 
tapped. In its January 1982 issue, Tax  Shelter  Insider  projected 
that the market for R&D partnerships will increase from $160 mil-
lion in 1981 to $2.25 billion in 1990. In fact, many people believe 
that R&D partnerships will soon surpass conventional venture 
capital funds in providing seed capital and early-stage financing 
to companies conducting R&D. 
R&D financing arrangements can be very complex. If you 
are an entrepreneur in search of R&D funding and are considering 
R&D partnerships, you undoubtedly have many questions and 
concerns. 
We at Deloitte Haskins & Sells have been advising clients 
and assisting them in arranging R&D financing for many years. 
As a result of that experience, we have prepared this guidebook 
to answer your questions and assist you in understanding and 
assessing the potentials of R&D partnerships. 
This guidebook is divided into two parts — a main text 
and a section of appendices. The main text provides general 
information to help you understand the workings of R&D partner-
ships and to explain how you go about forming one. The section 
of appendices spells out the many tax and accounting issues that 
you and your advisors must consider if your company is to 
achieve its goals. 
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The main text contains the following sections: 
• The structure of R&D partnerships. This section explains 
how R&D partnerships work and how they provide "up 
front" tax benefits to the investors. 
• Designing buy-outs. R&D partnerships are differentiated 
by the design of their buy-out arrangements. This section 
explains the purpose of the various arrangements, when 
each would be appropriate, and why. 
• Should you form an R&D partnership? This form of financ-
ing is not for everyone. The guidebook analyzes signifi-
cant factors that should be considered and compares the 
merits of R&D partnerships to debt and equity arrange-
ments. It also discusses the types of companies that are 
well suited for an R&D partnership. 
• What investors look for.  To successfully market an R&D 
partnership, you must understand the investors' perspec-
tive. This section examines the features of R&D partner-
ships that attract investors and the drawbacks of R&D 
partnerships as an investment vehicle. It also discusses 
the risks that prudent investors should evaluate and the 
factors they should consider in analyzing the terms of an 
offering. 
• Implementing a program. Implementation starts with a 
business plan. Then you must decide on a marketing 
strategy, draft  the documents, and arrange for ongoing 
management of the program. 
• Case studies. A benefit of R&D partnerships is the flexi-
bility you have in designing the arrangements. To illus-
trate, we present seven different  R&D partnerships which 
have been organized. These partnerships run the gamut 
from seed money to start a new company to a $55 million 
public offering. 
We also include three extensive appendices: 
• Tax considerations for the partnership. The agreements 
must be carefully written to assure that the expected tax 
benefits do, in fact, materialize for your investors. We ex-
plain in detail all the tax issues you and your advisors 
must consider when drafting the documents. 
• Tax considerations for the sponsoring company. The 
funds you receive are taxable as revenue, but you can take 
steps to avoid using a substantial portion of those funds 
to pay income taxes. This appendix also covers (1)the 
deductibility of royalty payments, and (2) potential prob-
lems you may encounter with the allocation of income 
and deductions. 
• Accounting implications. The ability to treat your R&D 
arrangement as "off  balance sheet financing" will depend 
on how the arrangement is structured. This appendix 
explains the implications of Statement of Financial 
Accounting Standards No. 68, which prescribes the 
accounting treatment companies with R&D contracts 
should use. This appendix also discusses the accounting 
issues related to buy-out transactions. 
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THE STRUCTURE OF 
R&D PARTNERSHIPS 
R&D partnerships give companies another option for 
financing research and development. Instead of using debt pro-
vided by lenders, equity provided by stockholders, or cash 
provided by internal operations, a company can look to investors 
seeking an attractive tax shelter opportunity. 
Many well-known companies have used R&D partnerships 
to raise money to develop a variety of products: 
• Lear Fan, in an early R&D partnership, raised $25,000,000 
to develop a fuel-efficient,  turboprop plane. 
• Storage Technology Corporation, in two private offerings, 
raised $95,000,000 to develop a high-performance  com-
puter and an optical disk drive. This $95,000,000 is the 
largest amount raised to date by a single company 
through R&D partnerships. 
• Trilogy Limited raised $55,000,000 to start Gene Amdahl's 
new company and to develop a high-performance 
computer. The first  large public offering  of its kind, it was 
rumored to have sold out in four hours. 
• Syntex Corporation raised $23,500,000 in December 1982 
to develop five different  medical diagnostic products. 
• Genentech, Inc. raised $55,000,000 in December 1982 to 
develop human growth hormone and gamma interferon 
products. Six months later, Genentech raised an addi-
tional $32,000,000 through a second partnership to 
develop a tissue-type plasminogen activator. 
The terms of R&D arrangements vary as widely as the pro-
ducts they help create. However, the general concept of R&D 
partnerships is very straightforward. 
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In a typical R&D partnership arrangement, there are two 
parties - a limited partnership and a sponsoring company. The 
two parties enter into a contract under which the sponsoring 
company will develop the technology for the limited partnership. 
The Limited Partnership 
R&D arrangements are generally limited partnerships. In 
such partnerships the limited partners, like the stockholders of a 
corporation, have limited liability. But unlike corporations, part-
nerships are not taxable entities. Items of partnership income 
and loss are allocated to the various partners, who then combine 
these items with other items of income and loss on their individ-
ual tax returns. Consequently, investors can use their share of 
any partnership losses to offset  other income they have earned, 
reducing their total taxable income and, therefore,  their taxes. 
In an R&D limited partnership, a general partner (or part-
ners) provides the management. The sponsoring company (or its 
subsidiary or other affiliate)  or a non-related party serves as the 
general partner. 
The limited partners are the individual investors. They do 
not actively participate in the management of the partnership. 
The limited partners, who are generally in the higher income tax 
brackets, provide capital to the partnership and benefit from tax 
deductions generated by the partnership's expenditures for 
research and development. 
The Sponsoring Company 
The sponsoring company is an entity that wants to fund 
an R&D project. It usually possesses the "base technology" to 
develop what it anticipates will be a commercially successful 
product. 
The sponsoring company must make the base technology 
available to the partnership. If the company wants to retain ac-
cess to the technology to use it in products other than the one to 
be developed by the partnership, the company can either: 
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• give the partnership a non-exclusive license to use the 
technology in the specific project in exchange for a 
license fee, or 
• enter into a cross-licensing agreement — the company 
gives the partnership a license to use the technology in 
the R&D project and the partnership gives the company a 
license to use the technology in other applications. 
The R&D Contract 
The limited partnership and the sponsoring company 
enter into a contract under which the company agrees to perform 
R&D work to develop a technology for the partnership. The com-
pany performs the development work on a best-efforts  basis, i.e., 
it does not guarantee any results. The partnership compensates 
the company on either a fixed-fee  or a cost-plus basis. 
The use of an R&D contract between a sponsoring com-
pany and a limited partnership gives rise to a current  tax  deduc-
tion  for the limited partners. The tax deduction is based on two 
tax authorities: Section 174 of the Internal Revenue Code (the 
Code) and the case of Snow vs.  Commissioner. 1 
Sec. 174 allows a taxpayer to deduct R&D costs as paid or 
incurred, rather than to capitalize them as part of the product's ul-
timate cost. 
Before 1974, the Internal Revenue Service (IRS) con-
tended that a taxpayer was not entitled to a deduction under 
Sec. 174 unless and until the taxpayer was "carrying on" a trade 
or business. Further, the IRS felt this criterion was not met 
unless the taxpayer was generating revenue or actively offering  a 
product for sale. In the precedent-sett ing Snow vs. 
Commissioner  case, the U.S. Supreme Court ruled that it was 
sufficient  for the taxpayer to incur the expenses "in connection 
with" a trade or business. This broad language supports Sec. 174 
deductions in a great variety of R&D arrangements. Most tax 
practitioners agree that as long as the partners incur substantial 
business risks and have a reasonable expectation of profit,  the 
arrangements meet the "in connection with" a trade or business 
requirement. 
1 Edwin A. Snow, 416 US 500 (1974)(33 AFTR2d 74-1251, 74-1 USTC para. 9432). 
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Under Sec. 174, partners may be allowed deductions in 
the year the partnership makes payments under an R&D contract. 
Consequently, when an R&D partnership enters into a contract 
with a sponsoring company, the partners' investments are im-
mediately used to prepay all or some of the contract costs. In this 
way, the partners are allowed deductions in the year their invest-
ments are made, even if the investments are not made until late in 
the year. 
Neither does the sponsoring company have to spend any 
of the funds before year-end. The partners will generally qualify 
for the "up front" deductions as long as the contract prepay-
ments are not construed as deposits and sufficient  business 
reasons exist for prepaying the contract costs. 
For a limited partner in the highest income tax bracket, 
this tax deduction immediately reduces the amount at risk and 
nearly doubles the potential rate of return. In contrast, investors 
who purchase stock in a company receive no tax deductions. 
Consequently, investors who are looking for a specified rate of 
return should be satisfied with lower cash returns as limited part-
ners in an R&D arrangement than as shareholders in a corpora-
tion. 
(NOTE: Throughout this guidebook we mention various tax 
aspects of R&D partnerships because these aspects are impor-
tant in understanding why R&D partnerships are structured as 
they are. However, the taxation of R&D partnerships is a complex 
subject. We devote Appendix I to a detailed explanation of the 
many tax issues.) 
The Buy-Out 
The limited partnership owns the rights to the results of 
the R&D project. When the R&D work is completed, the sponsor-
ing company usually exercises its option to acquire these rights 
from the partnership through three basic types of arrangements 
— royalty, equity, and joint venture. 
Royalty Partnerships 
In the typical royalty partnership arrangement, the 
company exercises an option to either: (1) purchase the 
technology, (2) purchase the partnership interests of the limited 
partners, or (3) acquire an exclusive license to use the technology 
to manufacture and market the resulting product. In exchange, 
the company pays the partners or the partnership royalties based 
upon sales of products using the technology. 
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Royalty rates frequently range from 6% to 10% of gross 
sales. The rate may remain constant or decline as the sales 
volume reaches certain levels. There may also be an upper limit, 
or cap, on cumulative royalties paid; a specified time period that 
royalties must be paid; or minimum and/or maximum limits on an-
nual royalties paid. 
The company may have an option to pay the partnership a 
lump-sum cash amount instead of royalties, either at the time the 
purchase option is exercised or at later dates. In some instances, 
if the company chooses a lump-sum payment, the partnership 
can opt for that payment in cash, company stock, or a combina-
tion of both. 
Equity Partnerships 
In the typical equity partnership arrangement, the part-
nership and the company agree to form a new corporation after 
the technology is developed. The partnership interests can, at the 
partners' option, be converted in a tax-free transaction to equity 
in the new corporation, based upon a formula set when the R&D 
contract was negotiated. In this way, the partner/investor winds 
up with an equity interest in the continuing entity. 
Pure equity partnerships are designed to launch new 
companies. Such partnerships usually provide seed capital or 
first-round  financing for new ventures. Closely resembling a ven-
ture-capital type of investment, an equity partnership provides 
the investor with the added advantage of current tax deductions. 
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The early equity R&D partnerships were established with 
the entrepreneur as general partner and the tax-oriented inves-
tors as limited partners. 
In recent versions, the entrepreneur forms a corporation 
and obtains traditional venture capital investors. The entrepre-
neur and key employees receive common stock and/or options, 
while the investors receive a series of preferred  stock. Funds 
provided by the venture capitalists are used for non-R&D expendi-
tures. 
A limited partnership is then organized with the corpora-
tion as the general partner and tax-oriented investors as the 
limited partners. The corporation contracts with the R&D partner-
ship to perform the development work, using funds invested by 
the limited partners. The limited partners are usually allocated 
99% of the contract costs as Sec. 174 deductions. 
Partnership income is allocated on a negotiated basis. In 
actual practice, the partnership probably will never realize in-
come. The profit  allocation's real purpose is to define the relative 
interests of the parties so that stock can later be proportionately 
distributed. 
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Figure 1-2: Equity Partnerships 
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When the technology is developed, the partners ex-
change their interests in the partnership and the shareholders of 
the corporation exchange their shares of stock for the stock of a 
successor corporation in a tax-free transaction. The successor 
company manufactures and markets the new product. 
This equity partnership arrangement works well when 
(1) significant funds for non-R&D expenditures are needed, and 
(2) some investors do not need current tax deductions but are 
willing to participate side by side with tax-advantaged investors. 
Joint Ventures 
In a joint venture arrangement, the company and the 
partnership form a joint venture to manufacture and market the 
product after the technology has been developed. At some point 
the company buys out the partnership's interest in the joint ven-
ture, or vice-versa, pursuant to cross-purchase options in the 
joint venture agreement. 
Figure 1-3: Joint Ventures 
R & D Funds 
R & D 







From the company's perspective, the formation of the 
joint venture is an interim step which allows the company to start 
production and marketing. During this period, profits (which may 
not be significant at the initial sales levels) are split between the 
company and the partnership. Since these profits are normally 
less than royalty payments, the company has more funds to use 
in operations during this period. After a period of time, the com-
pany exercises an option to purchase the partnership interests. 
In practice, the joint venture is most often used only as a 
vehicle to meet several criteria for advantageous tax treatment 
for the partners. The tax treatments available to the partnership 
are an important consideration in structuring an R&D partnership 
arrangement, and are a primary factor in determining what type of 
buy-out arrangement should be used. Section 2 discusses at 
length the implications of the various arrangements. 
Variations 
As R&D arrangements proliferate,  new features are con-
stantly being devised to suit the particular circumstances of each 
situation. Each arrangement reflects trade-offs  among the risks, 
the rewards, and the needs of the investors and the sponsoring 
company. Some recent popular techniques include: 
Hybrid Arrangements 
In an increasingly popular hybrid of royalty and equity 
arrangements, the company issues warrants entitling the partner-
ship to purchase stock. Consequently, the partnership receives 
both royalties and a right to acquire equity in the sponsoring 
company. 
The equity portions of the arrangement are added when 
the tax advantages are not sufficient  to entice investors, or when 
the investors will participate in the partnership primarily to be 
able to acquire that equity in the sponsoring company. 
With its R&D offering  in June 1983, Cetus, Inc. issued 
warrants to purchase stock at $23 per share, exercisable for four 
years. At the time of issuance, Cetus common stock was trading 
at $20 per share. The investors have two potential ways of receiv-
ing a return on the investment — through the payback on the 
R&D partnership itself and/or through increases in the market 
value of the sponsoring company's stock. Consequently, their 
risk is reduced. The Cetus arrangement reflects the current trend 
of including warrants in publicly-syndicated offerings  to make 
those offerings  more marketable. 
18 
Blind Pools 
Brokerage houses and R&D and venture capital funding 
groups have recently begun sponsoring blind pool R&D partner-
ships. Many people believe blind pools will soon be the largest 
vehicles for marketing R&D partnerships. 
Investors invest in blind pools rather than in specific 
ventures. The sponsors then use the pooled funds to invest in a 
variety of ventures in a manner similar to venture capital funds. 
Because a new group of investors need not be formed for 
each new venture, R&D should be easier and less expensive to 
form and to market. More important, however, investors have the 
added benefit of spreading their risk among several projects. 
Non-tax-oriented Investors 
Investors often are interested in certain R&D arrange-
ments, but have no need for current tax deductions. A partner-
ship may be established with two classes of limited partners. Tax-
oriented investors are allocated all of the R&D deductions, while 
non-tax-oriented investors purchase limited-partnership interests 
at a reduced price (generally about 20% less) in lieu of any tax 
benefits. The Alpha Partners case in Section 6 is an example of 
such a partnership. 
Tax Advantaged Start-up Partnerships 
A start-up company can be established as a partnership, 
where the founder serves as the general partner and venture 
capitalists purchase limited partnership units. The partnership 
performs the R&D and begins to market the product. Just before 
the partnership begins to show a profit,  the partners can opt to in-
corporate and convert the partnership units, tax-free, into shares 
of the new corporation. 
These types of partnerships are not actually R&D part-
nerships; however, the start-up partnership (like the equity R&D 
partnership) provides equity investors with some tax benefits. 
Start-up partnerships have actually been used for many decades, 
but they are now experiencing renewed popularity, in part be-
cause of the popularity of R&D equity partnerships. 
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In a start-up partnership, the expenses incurred by the 
partnership do not flow through to the partners until those expen-
ditures are actually made. Consequently, the tax benefits are not 
realized by the partners as quickly as the benefits of an R&D equi-
ty partnership. However, the start-up partnerships are much 
simpler and cheaper to organize, and are not subject to some of 
the tax issues surrounding R&D partnerships. 
In another variation of this, many emerging companies 
today are establishing partnerships or joint ventures to which the 
companies contribute a developed product. The venture is formed 
to finance the costs of marketing that product and the costs to 
develop the next generation of products or an entirely different 
product. Because the venture is carrying on a trade or business 
from the onset, the partners/investors are allowed to deduct the 
marketing costs related to the existing product as well as pre-
market and development costs for successor ones. In effect, 
investors make second or third round financing investments 
through a tax-advantaged vehicle. 
Corporate R&D Arrangements 
Many companies are beginning to create R&D joint 
ventures with other companies in order to pool their resources 
and to share the research results. For example, Microelectronics 
and Computer Technology Corp. was formed in 1982 by fourteen 
sponsoring companies, including Honeywell, Digital Equipment, 
Motorola, National Semiconductor, and NCR. With an anticipated 
annual budget of $50-100 million, it represents a cooperative ef-
fort  to develop a broad base of fundamental technologies for use 
by the member companies. The expectation is that each sponsor 
will then build on the basic technology and continue to compete 
with each other with products and services of individual concep-
tion and design. As another example, Hewlett Packard Co. and 
Genentech Inc. agreed in July 1983 to begin a joint venture to de-
velop instruments for the biotechnology industry. 
While these do not represent R&D partnerships in the 
usual sense, they are R&D partnerships nonetheless, represent-
ing a new trend in the way that American companies are funding 
R&D. 
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2. DESIGNING BUY OUTS 
Section 1235 — Sale of  Patents 
Sections 1221-23 and Section 1231 
Other Techniques for  Capital Gains 
Treatment 
Executing the Buy-Out 
SECTION 2 
The ideal tax shelter permits income to be treated as long-
term capital gains. Such gains are taxed at a maximum rate of 
20%, as opposed to a maximum rate of 50% on ordinary income. 
Most R&D partnership buy-out arrangements are designed with 
this tax consideration in mind. 
For investors, the possibility of receiving capital gains 
treatment on income from R&D partnerships is a major attraction. 
It is also a significant factor in increasing the investors' potential 
rate of return. R&D partnerships can achieve capital gains treat-
ment on buy-out arrangements by making use of various Code 
sections. 
Section 1235 - Sale of Patents 
Under Sec. 1235 the sale by a qualified holder of all sub-
stantial rights to a patent or patentable technology will be taxed 
as long-term capital gains, regardless of the holding period. 
Sec. 1235 has two advantages over other available Code 
sections. The partnership is not required to establish the twelve-
month holding period that is normally required for long-term 
capital gains status; so it can sell the technology as soon as the 
research contract is completed. Additionally, property sold under 
Sec. 1235 is automatically considered a capital asset, avoiding 
the issue of whether the technology is inventory (see discussion 
below). 
However, the use of Sec. 1235 is limited, primarily 
because of the following: 
• The requirements to qualify the partners as "holders" are 
elaborate and, in some cases, the base technology 
cannot be transferred  so that the limited partners qualify. 
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• Sec. 1235 only applies to patentable technology or to that 
portion of a technology that is patentable. For example, 
with a computer system that includes both patentable 
hardware and nonpatentable software, Sec. 1235 would 
not apply to the software portion. 
Sections 1221-23 and Section 1231 
In those situations where Sec. 1235 does not apply, the 
partners may be able to receive long-term capital gains treatment 
on the sale of the technology, relying on Secs. 1221-23 (capital 
assets) or Sec. 1231 (property used in a trade or business). 
Under these Code sections, the invention need not be 
patentable. To qualify, however, the technology must be viewed 
by the IRS as a capital asset. That is, the technology cannot be 
viewed as inventory — property held primarily for sale to cus-
tomers in the ordinary course of the partnership's trade or 
business. 
Additionally, the technology must be held by the partner-
ship for at least twelve months from the time the technology was 
reduced to practice. Consequently, many technology purchase 
options specify that such options are not exercisable until a cer-
tain period after  the technology is reduced to practice. In the 
meantime, the technology is used either by a joint venture of the 
partnership and the sponsoring company, or by the sponsoring 
company under a non-exclusive short-term license from the 
partnership.2 
Other Techniques for Capital Gains 
Treatment 
Tax complications sometimes arise when technology is 
acquired with reliance on Secs. 1221-23 and 1231 for capital 
gains tax treatment. Some of these issues (such as whether the 
asset constitutes property, whether a complete sale has 
2 If the technology is subject to rapid obsolescence, this strategy of licensing the 
technology may not be practical. In such a case, the greatest revenue from the 
technology is likely to be earned during the license period, and all this income 
would be ordinary income. Only a small amount might ultimately be eligible for 
long-term capital gains treatment. In contrast, the likelihood of capital gains 
would be considerably greater in a Sec. 1235 arrangement. Therefore,  some 
practitioners advise that, in evaluating actual yield, the investor should assume 
that the return in non-Sec. 1235 arrangements will be ordinary income and make a 
judgment on the feasibility of the investment accordingly. 
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occurred or whether the tax benefit rule applies) may be avoided 
by having the partners sell their partnership interests rather than 
the technology. If the partnership interest has been held for one 
year or more, its sale qualifies for capital gains treatment. (Some 
of the gain will be treated as ordinary income if the partnership 
assets included receivables unrecognized for tax purposes or if 
the assets included inventory. The partnership may still need to 
hold the technology for a year to qualify the technology as a 
capital asset and avoid taxation of that portion of the gain as 
ordinary income. See Appendix I.) 
Still other techniques to acquire the technology include 
incorporation of the partnership or a tax-free merger of the part-
nership into the sponsoring company (where the stock received 
can later be sold as a capital asset). Either of these techniques 
can result in the partners receiving capital gains treatment, but 
because they are not unique to R&D partnerships, the tax issues 
and requirements will not be addressed here. 
Executing the Buy-Out 
The three basic types of buy-out arrangements are 
designed to take advantage of the Code sections allowing for 
capital gains treatment. 
Most royalty partnerships are structured to attempt to 
qualify for capital gains treatment under Sec. 1235, purchase of 
the partnership interest, and Secs. 1221-23 and Sec. 1231 as well. 
The partnership usually provides the company with a review pe-
riod/option period of twelve months or more prior to the time the 
company has the right to purchase the technology. 
Often, a joint venture is used solely for the purpose of 
creating that holding period. After the development work is com-
pleted, the partnership and the sponsoring company form a joint 
venture. The partnership gives the joint venture a short-term li-
cense to use the technology for at least twelve months after the 
technology is reduced to practice. At the end of that period, the 
company has an option to buy the technology or the partnership 
interest by paying royalties or by making a lump-sum payment. 
For example, see the Diversified Technology arrangement de-
scribed in Section 6. 
In addition to meeting the partnership's holding period 
requirements, the joint venture establishes that the technology 
was not developed solely for sale but for the primary purpose of 
applying the technology to the manufacture of products for sale. 
Consequently, the partnership avoids the issue of whether the 
technology constitutes inventory. 
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You must be careful  that the purchase option and the joint 
venture agreement are not too similar and that the joint venture 
agreement is not more detrimental to the sponsoring company 
than the purchase option. Otherwise, the IRS may ignore the joint 
venture arrangement and assert that the purchase option was in 
substance exercised at the time the joint venture was set up. This 
assertion would destroy your twelve-month holding period. To 
avoid this problem, many purchase options require a substantial 
payment at the time the option is exercised. The payment may be 
applied against future royalties, but the need for the company to 
make that payment in advance is an indication that the purchase 
option is more detrimental to the company than the joint venture 
arrangement. 
In another type of joint venture arrangement, the 
company and the limited partnership form a joint venture to both 
develop and commercially exploit a technology or product. The 
partnership contributes cash for the initial funding of the joint 
venture, while the company contributes management and a li-
cense to existing technology. The joint venture then contracts 
with the company to perform the development work. After  devel-
opment is completed, the joint venture (rather than the company) 
will attempt to exploit the new product. It will contract with the 
company to manufacture the product, and it will sell the product 
either directly or through the company. The company usually has 
the option to buy out the limited partnership's interest in the joint 
venture after a specified period. Because the joint venture may be 
viewed as carrying on a trade or business, this type of arrange-
ment may allow the joint venture (and, consequently, the limited 
partner) to deduct certain non-R&D expenditures. Any income 
generated by the joint venture will be taxed as ordinary income, 
but the gain from the sale of the joint venture or limited 
partnership interest may be taxed as long-term capital gains (ex-
cept for that portion representing substantially appreciated in-
ventory — see Appendix I). 
With equity arrangements, the expectation is that if the 
development is successful the partnership interests will be ex-
changed into shares of the sponsor company or a new company. 
In these and other buy-outs for stock, the treatment of the trans-
action as nontaxable is critical because investors may not have 
the cash with which to pay the related taxes. In a merger of a 
company and a partnership into a new company, additional con-
tributions from corporate shareholders may be necessary to 
qualify the transaction as tax-free. When the stockholders sell 
their shares of stock, they may recognize capital gains. 
When forming an R&D partnership, you must decide what 
Code sections will apply to your situation, so that the right ar-
rangement can be selected, so that the buy-out will take place at 
the appropriate time, and so that nothing is done at formation 
that would preclude the partnership from receiving capital gains 
treatment. 
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3. SHOULD YOU FORM AN 
R & D PARTNERSHIP? 
Advantages 
Disadvantages 
Are You a Potential Candidate for 
R&D Partnership Funding? 
SECTION 3 
SHOULD YOU FORM AN 
R&D PARTNERSHIP? 
R&D partnerships are now an acceptable source of 
financing for companies in every stage of development and of 
every size. But they may not be the best source for everyone. If 
you are seeking R&D funding, you should carefully compare the 
merits of R&D partnerships to those of debt and equity 
arrangements. 
Advantages 
R&D partnership financing provides many attractions to 
the sponsoring company. The major benefits include: 
Less Dilution 
When R&D royalty partnerships came into vogue in the 
late 1970s, an often-stated reason for companies to use them was 
to avoid the dilution to current shareholders which would occur if 
additional stock were sold to fund the R&D. For example, Gene 
Amdahl was said to have selected an R&D partnership for his new 
company, Trilogy Limited, so that his interest in Trilogy would not 
suffer  the dilution his interest in Amdahl Corporation had 
suffered. 
The dilution impact can be significant. A Silicon Valley 
company that recently sought first-round  financing found that 
out quickly. 
The founders of this company had contributed $125,000 
and had done preliminary R&D on their new product. They 
decided that an additional $3.5 million would be needed in the 
next 12-15 months for research and development expenditures, 
and another $1 million would subsequently be needed for start-up 
manufacturing and initial marketing. Additionally, the company 
wanted to establish a 35% equity participation plan for its man-
agement team. The company negotiated financing proposals 
with two different  venture capital groups as follows: 
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Option 1 Investment Equity 
Founders (original investment) $ 125,000 
Management stock purchase plan (notes) 350,000 







Founders (original investment) $ 125,000 24% 
Management stock purchase plan (notes) 135,000 35% 
R&D royalty partnership* 3,500,000 7% 
Venture capital investors 1,500,000 34% 
Total $5,260,000 100% 
* The R&D partnership called for royalties with a cap of 3.5 times 
the amount invested plus warrants to purchase a 7% interest 
in the company. 
In Option 1 - an equity venture capital placement - only 
$3.5 million could be raised, and the company had to give up a 
60% interest in the company. It could not raise the entire $5 mil-
lion and still retain 35% of the equity for its management team. 
Therefore,  it would have to seek second-round financing before 
proving the product's marketability and the company's ability to 
profitably produce it. 
In Option 2 - a combination of equity venture capital and 
an R&D partnership - the company was able to raise $5,000,000. 
With this option, the next round of financing would not have to 
occur until the company had assessed its marketing and produc-
tion risks. At the same time, the founders and management 
retained much greater ownership. They received 43% more capi-
tal, yet retained a 59% ownership position - 48% more 
ownership than under the first  option. Of course, there may be a 
substantial cost to the company later. If the project is successful, 
the company will have to pay up to $12 million in royalties. 
With equity and joint venture arrangements, dilution ob-
viously cannot be avoided, since these arrangements are de-
signed to convert partnership interests into equity interests in 
your company. Dilution occurs eventually, but will still not be as 
significant as the dilution in a pure equity placement. While the 
conventional venture capital investor may want to end up with 
45% to 65% of a company, the equity partnership investor will 
settle for 30% to 50% in the same situation. Because the latter 
receives up-front tax benefits, the after-tax return on investment 
is comparable. 
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Even with royalty arrangements, the avoidance of dilution 
may be illusory. If royalties are to be paid out at a high rate, you 
may find it difficult  to face the commitment on a long-term basis 
and be forced to buy out the partnership interests. If you have no 
cash for the buy-out, you may have to give the partners an equity 
interest, resulting in the very dilution you initially set out to avoid. 
The ultimate dilution, however, would still be less than if you had 
initially raised equity capital to finance your company. 
So even if you can't avoid dilution entirely, you can expect 
less dilution. Additionally, if some or all of your R&D effort  can be 
accomplished through the R&D partnership, subsequent venture 
capital financing will require even less loss of equity. Once you 
have completed the development of your product or have a 
prototype in place, your risks will have been reduced, so that the 
venture capitalist providing second-round financing will settle for 
a smaller share of your company. 
Transfer  of Risk 
In many cases, research and development projects repre-
sent substantial risk to a company. A significant benefit of R&D 
partnership funding is that the risk is borne by the limited part-
ners rather than the company. R&D partnerships allow you to in-
sulate your business from the risk of a new project failing. There 
is no cost or other risk of loss to you if the product cannot be de-
veloped. You pay only for successful development and sale of the 
product. 
In reality, however, you may find it very difficult  to com-
pletely walk away from an unsuccessful project. You will create ill 
will in the investor/partners and in the general investment com-
munity that may cause long-term problems for your company. 
The value of your company's stock may be adversely affected  be-
cause of the company's association with a well-publicized unsuc-
cessful program. And if stock analysts perceive the R&D program 
to be critical to your company, the program's failure could also af-
fect the stock value. 
Retention of Control 
With less dilution, you retain greater control of your com-
pany and, consequently, control over the direction of the 
product 's development. However, the general partner 
(independent or not) does  have a fiduciary responsibility to 
monitor the progress of the R&D project and to insure that you 
are adhering to contract specifications. 
31 
Reacquisition Rights 
If the R&D project is successful, R&D partnership 
arrangements allow you to reacquire all rights to the product. 
Accounting Treatment 
If the R&D partnership bears the risk of loss if the project 
is unsuccessful, then the R&D arrangement will have a favorable 
impact on your company's financial statements during the years 
of the project. Your R&D expenditures are offset  by revenues 
received from R&D contracts. In effect,  your company's earnings 
are not affected  by your R&D efforts.  To illustrate, if you were to 
undertake a $1,000,000 R&D project with either (1) a cost-
plus-10% R&D contract, (2) borrowings at 15% interest, or (3) 
equity, your earnings would be affected  as follows: 
R&D Debt Equity 
Partnership Financing Financing 
Contract revenue $1,100,000 
R&D expense (1,000,000) $(1,000,000) $(1,000,000) 
Interest expense (150,000) 
Pre-tax effect 100,000 (1,150,000) (1,000,000) 
Income taxes (at 50%) (50,000) 575,000 500,000 
R&D tax credit* 100,000 100,000 
After-tax effect 
on earnings $ 50,000 $ (475,000) $ (400,000) 
* Assumes that 80% of expenditures qualify. 
With R&D partnerships, should you exercise your option 
to reacquire the rights to the technology, you purchase those 
rights with royalties on future revenue or with lump-sum pay-
ments of cash and/or stock. This makes it possible for you to 
match the expense of the technology development (royalty ex-
pense or amortization of product rights) with revenues received 
from products using the technology. This impact on your finan-
cial statements can have a positive effect  in subsequent equity 
offerings  or attempts to acquire additional debt. 
Properly structured, an R&D partnership also provides 
"off  balance sheet financing," i.e.,  you do not show the funds 
from the partnership as debt on your financial statements. Con-
sequently, your debt-equity ratio, a ratio that lenders evaluate 
critically, is improved. A company funding its R&D with a limited 
partnership is likely to be extended more credit than a company 
funding its R&D with debt, assuming all other factors are the 
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same. The debt-funded company may actually be healthier finan-
cially, since its debt burden is probably not as substantial as the 
other company's royalty commitment. However, its higher debt-
equity ratio can result in it receiving less credit. 
The accounting treatment of R&D arrangements is depen-
dent on the way the arrangements are structured. The accounting 
issues are discussed in detail in Appendix III. 
Better Cash Flow 
The R&D partnership approach helps you avoid the initial 
debt-service requirements. Debt may produce much earlier nega-
tive cash flow since the typical loan requires that, shortly after 
getting the loan, you begin repaying it in periodic installments. 
Royalty payments for R&D partnership funds commence only 
after the research has been completed, the technology has been 
acquired, and sales of the product have commenced. 
It also allows you to conserve your debt capacity, which 
can be used for other purposes. 
Disadvantages 
There are also some very significant disadvantages to 
R&D partnerships. 
High Cost of Capital 
If successful, the cost of R&D funds is very expensive to 
the sponsoring company. Because of the risks inherent in R&D 
projects, the investors' return must be greater than the return of-
fered by less risky ventures. The cost generally ranges from 
25%-45% on an annualized after-tax basis, plus the benefit of 
R&D tax credits is lost. Generally, R&D partnerships will be less 
expensive than equity, but more costly than debt. 
The following table compares the cost of funding a 
$1,000,000 R&D project with (1) a 15% loan, and (2) an R&D part-
nership designed to provide the investors with a 50% pre-tax rate 
of return on their net investment. 
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Length of Project 
2 Years 4 Years 6 Years 
Debt Funding 
Loan proceeds $1,000,000 $1,000,000 $1,000,000 
Interest expense (300,000) (600,000) (900,000) 
Tax benefit 150,000 300,000 450,000 
R&D expense (1,000,000) (1,000,000) (1,000,000) 
Tax benefit 500,000 500,000 500,000 
R&D tax credit* 100,000 100,000 100,000 
Loan repayment at 
end of project (1,000,000) (1,000,000) (1,000,000) 
Earnings on excess 
funds** 26,300 71,300 105,600 
Net project cost $ 523,700 $ 628,700 $ 744,400 
Partnership Funding 
R&D contract proceeds $1,000,000 $1,000,000 $1,000,000 
Tax expense (500,000) (500,000) (500,000) 
R&D expense (1,000,000) (1,000,000) (1,000,000) 
Tax benefit 500,000 500,000 500,000 
Royalty payments (1,125,000) (2,531,250) (5,695,310) 
Tax benefit 562,500 1,265,625 2,847,655 
Net project cost $ 562,500 $1,265,625 $2,847,655 
* The tax credit was calculated with the assumption that 80% of 
the expenditures will qualify for the credit. 
** At the end of the first  year, the company will actually have 
$525,000 of positive cash flow. That amount is assumed to be 
invested at 10% and used to pay the interest costs of 
subsequent years. 
For a project requiring two years from the beginning until 
the company pays off  the loan or buys out the partnership, the 
cost difference  between the debt-funded project and the partner-
ship-funded project is not significant. However, the longer the 
project, the greater the difference  in cost. 
High Royalty Provisions 
If royalty provisions are too high, they can eat into profit 
margins. Gross margins on products subject to royalties must be 
at least 40-50%; otherwise, margins after royalty payments may 
be too low to offer  any incentive to market the products. Con-




The funds from R&D partnerships are restricted for R&D 
expenses (as defined in the R&D contract) related to a specific 
project. The project may require other funding, i.e.,  funds may be 
required for market surveys, production equipment, etc. Al-
though these expenditures may be funded out of profits realized 
on the R&D contract, you may still need to secure equity or debt 
financing to fulfill  all your needs. 
Expensive to Establish 
Creating R&D partnerships is expensive and time-con-
suming. Management must devote much time to the effort,  and 
fees may have to be paid to underwriters, attorneys, accountants, 
and the general partner. After  the partnership is formed, partner-
ship records must be maintained and tax returns must be filed. 
Potential Impact on Subsequent Public Offering 
You may be contemplating a future public stock offering 
for your company. If so, you must consider whether the royalties 
to be paid are so high that earnings during the years before the of-
fering will be too low for your stock to command the appropriate 
price. If at the time of your offering  you have significant royalty 
commitments, the public offering  valuation will be adversely af-
fected. Even if you can get out from under the commitments 
created by the R&D partnership before the offering,  analysts un-
derstand that a lump-sum cash or stock buy-out will require you 
to amortize the capitalized cost. That amortization will reduce fu-
ture financial-statement earnings, whereas a company that has 
funded R&D with debt or equity has already recognized its R&D 
costs. This factor can affect  the public offering  valuation 
substantially. 
Are You a Potential Candidate for R&D 
Partnership Funding? 
R&D partnership financing can be appropriate for com-
panies of all sizes and in varying stages of maturity. A start-up 
company can be an appropriate candidate, especially if substan-
tial R&D is required to develop that company's product. Venture 
capital equity is usually obtained to pay non-R&D expenses and 
to satisfy capital asset requirements. 
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Emerging companies that already have one or two exist-
ing products in the marketplace may also be good candidates. 
Partnership funds can be used to develop new products while the 
company's capital may be conserved to finance current growth. 
Established companies, including Fortune 500 compa-
nies, have also begun to finance new products recently through 
R&D partnerships. The funds are frequently used to develop pro-
ducts which, although related, are ancillary to the companies' 
primary business. 
A key consideration in determining whether an R&D 
partnership is appropriate is the size of the potential market for 
the products to be developed relative to the amount of develop-
ment funds required. The market must be big enough to provide 
investors with an attractive rate of return from royalties on sales 
of the products. 
It is also important that you have access to other capital 
to finance expenditures not related to R&D. R&D partnership 
financing is not, over the long-term, a substitute for debt and 
equity. Instead, it supplements these conventional capital 
sources. You may need to seek an appropriate mix of (1) debt for 
working capital and fixed asset acquisitions, (2) equity to support 
debt and to acquire fixed assets, and (3) R&D partnership funds to 
finance R&D projects. 
Before undertaking an R&D partnership arrangement, you 
should first  determine the related cost of capital and compare 
that cost to alternatives like debt and new equity. You can refer  to 
R&D offerings  made by other companies or get assistance from 
investment bankers, R&D partnership service firms, or your ac-
countants to determine the probable financing terms. You can 
then estimate the capital costs of partnership financing and com-
pare these costs with other available financing options. Weighing 
the costs with the other advantages and disadvantages we dis-
cussed in this section, you can then decide whether it is the 
appropriate course for you. 
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R&D partnerships have attracted the interest of many 
investors. These partnerships have some of the same allure as 
venture capital investments, as most of them offer  the opportu-
nity to participate in the development of glamorous technology 
and to make substantial financial profits.  Additionally, R&D 
partnerships often do not require as large an investment to par-
ticipate — some of the new blind pools require a minimum in-
vestment of only $5,000. 
Before you create an R&D partnership, you should be 
aware of what investors are seeking in these arrangements and of 
how these investors evaluate their potential return. 
What Attracts Investors 
Investors may find R&D partnerships attractive for many 
reasons: 
Current Tax Shelter 
They can deduct a substantial portion of their investment 
against their ordinary income. In non-leveraged deals, the deduc-
tion can be as much as 85% to 95% of the investment. This 
reduces the after-tax dollars which the investors have at risk and, 
for those in the highest tax brackets, also nearly doubles the 
potential return. 
Large Return 
To be marketable, most R&D partnership investments 
should pay a 45% to 55% after-tax rate of return on the investors' 
net investment. This is generally a yield of at least four times the 
investors' cash investment (the so-called "cash-on-cash" return) 
and could be even greater depending on how long it takes the 
investor to get that return. 
Payout at Capital Gains Rates 
Investors will also be attracted to arrangements that 
enable them to recognize income from their investment at long-
term capital gains rates. 
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Potential Equity Position 
Many R&D partnerships provide investors with the option 
to receive stock in the company in exchange for the rights to the 
technology. Therefore,  they can make an equity investment with 
the added advantage of up-front tax benefits. 
Earlier Payout 
With royalty R&D partnerships, investors begin receiving 
cash returns as soon as sales of the product commence, whether 
the company is generating profits or not. Consequently, these in-
vestors are paid back much sooner than those investors depen-
dent on the company's profitability. 
No Dependence on Profits 
With royalty arrangements, investors are somewhat insu-
lated from the uncertainty of the long-term profitability of a com-
pany. Because royalties are based on sales rather than profits,  in-
vestors need not be as concerned about whether the company 
will ultimately be profitable. Investors will, however, have some 
lingering concern because if the company is not profitable it may 
not exist long enough to meet its royalty commitments. 
The Drawbacks 
The potential financial rewards for R&D partnerships are 
very high because of the substantial risks involved. Most partner-
ships have investor suitability standards which require investors 
to meet certain net worth or annual income levels at the time the 
investment is made. 
As an investment vehicle, R&D partnerships also have 
some other disadvantages. 
No Liquidity 
The partnership units have no public market and are 
generally restricted as to transfer  (i.e.,  consent of the general 
partner). 
Possible Financing Shortfall 
The costs to develop a new product are never certain, and 
you face the possibility that additional funding may be required. 
Investors may need to contribute more money. Alternatively, new 
investors may need to be found, which could cause substantial 
dilution to the existing limited partners. 
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No Control over Business Decisions 
Limited partners have little or no control over business 
decisions. Quite often, the general partner is the sponsoring 
company, although independent general partners are appearing 
with more frequency. While independent general partners may 
avoid conflict-of-interest  problems, the limited partner investors 
still have no voice in any decisions. 
Close IRS Scrutiny 
The tax laws affecting  R&D partnerships are complex and, 
in many cases, vague. The IRS, in its quest to crack down on 
abusive tax shelters, is scrutinizing R&D partnership arrange-
ments carefully.  If the investors' tax benefits are disallowed, the 
investors' overall rate of return may be insufficient  for the risks 
they take. 
Assessing the Risks 
The tax shelter aspects of R&D partnership programs are 
very alluring to investors, and many promoters emphasize these 
aspects. However, prudent investors must assess the probability 
of receiving long-term financial returns on their investment. Just 
as a venture capitalist analyzes the risks before investing in a 
new business, your investors should analyze the economic 
realities and basic business risks inherent in your R&D partner-
ship arrangement. 
The technology risk — the risk that the proposed R&D 
project will not be successfully completed — is the first  risk that 
must be evaluated. R&D partnerships can run the gamut from 
high-risk, pure research deals to less risky, so-called "Big D" 
(mostly development) partnerships. Will the R&D effort  require 
state-of-the-art  research or will it be primarily development of 
existing technology? Does the sponsoring company have the 
technical ability to successfully complete the project? Can the 
project be completed with the funds provided by the R&D 
partnership? 
In evaluating R&D partnership investments, a prudent 
investor will not focus exclusively on the technology risk. Some 
say that the technology risk accounts for no more than 20% of 
the total risk; if the project is successful, then investors are 
exposed to a potpourri of other risks. 
• Management risk. The investors' long-term financial 
return will be dependent on future sales to generate royal-
ties or to generate income. Consequently, the company's 
management must be capable of running successful 
41 
production and marketing operations. Does the manage-
ment team have sufficient  skills to manage what could be 
a fairly complex organization? 
• Financing risk. Once the development is completed, the 
company will require additional capital to finance the 
production and marketing of the developed product. Will 
the company be able to obtain this additional capital? 
• Manufacturing risk. Researchers sometimes tend to do 
their work to create a prototype that performs according 
to planned specifications, but with little consideration 
given to building the prototype that can be mass pro-
duced efficiently.  This can be especially true with high 
technology development. Can this magnificent product 
actually be manufactured? Will manufacturing costs be 
so high that the product is essentially unsalable? Are 
critical components of the product in short supply? Are 
costs to manufacture the contemplated product changing 
so rapidly that the manufacturing risk is unacceptable? 
• Marketing risk. For investors to realize any substantial 
return on their investment, the product must be success-
fully marketed. Does the overall product concept make 
sense? Is there a need for the product? Is there a large 
potential market? Will it still be there when the product is 
ready? How realistic is the anticipated market share? 
What is the competitive environment? 
• High technology risks. Most R&D partnerships today are 
formed to develop high technology products. If investors 
can satisfy themselves as to all of the above risks, they 
must also evaluate the vigorous competition, rapid ob-
solescence and dynamic markets which generally charac-
terize the high technology industry and its products. 
If investors cannot be satisfied that the sponsoring com-
pany has a high probability of overcoming these risks, then no 
matter how high the potential return, they will not invest. 
Analyzing the Offering 
Once an investor is satisfied with the feasibility of the 
venture, the investor must analyze the terms of the offering.  The 
potential rate of return must be adequate given all the risks 
associated with the partnership. Many specialists feel that, 
considering the risks, a 45% to 55% annual rate of return is ap-
propriate for the R&D partnership investor. Depending on the par-
ticular circumstances, higher or lower rates may be appropriate. 
42 
A company can be saddled with royalty rates ranging from 
2% to 30% of sales, with maximum royalties ("a cap") ranging 
from three times the initial investment to unlimited royalty pay-
outs. In analyzing the pricing of the investment, investors should 
evaluate the probability that the company will attain its revenue 
projections. For example, Genentech's prospectus for its first 
R&D partnership contains a table showing the potential financial 
return to limited partners. The table is based on projected 
revenues of more than $8.1 billion from the developed product 
over fourteen and one-half years. 
How likely is it that the company will reach these sales 
levels? Investors should determine what their return would be if 
projected sales levels are not reached or if development is 
delayed. 
The investor should also make certain the arrangements 
are structured by experienced experts in such a way that the 
limited partners' interests will be protected and the potential tax 
benefits will be retained. 
A vast array of R&D partnerships of the "suede shoe" 
variety has appeared. Many boast multiple write-offs  in excess of 
five times the cash investment. Investors should view such 
partnerships with a high degree of skepticism, since the partner-
ships probably will be considered "abusive tax shelters" by the 
IRS. Without due diligence performed by the research group of a 
major investment banking firm or a competent professional 
general partner, the risks associated with R&D partnerships 
increase dramatically. 
Because R&D partnership financing is a relatively new 
investment vehicle, there is little information available on the 
successes of past R&D offerings.  One R&D partnership - an ar-
rangement with Metricon (a private Silicon Valley laser manufac-
turer) - received significant publicity when it was bought out 
within 18 months by Johnson & Johnson for reportedly five times 
the partnership's initial investment of $750,000. On the other 
hand, the first  DeLorean limited partnership appeared to be doing 
quite well when each of the $100,000 partnership units was con-
verted into 2,857 shares of $8.00 cumulative dividend convertible 
preferred  stock (which the company elected to issue in lieu of 
cash payments of $285,700 per unit); yet DeLorean Motor Com-
pany is now in receivership. 
For most of the R&D partnerships that have been formed, 
the results will not be known for some time. Clearly, they are 
high-risk investments. But if investors find one that appears to 
have a reasonable chance of success and is professionally 
structured, an R&D partnership can be an attractive tax-
advantaged investment opportunity. 
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The Impact of TEFRA 
The Tax Equity and Fiscal Responsibility Act of 1982 
(TEFRA) implemented several laws which reduced the tax 
benefits associated with various tax shelters. Beginning in 1983, 
investors have to include deductions for R&D expenditures 
as tax preference  items subject to the alternative minimum tax. 
The alternative minimum tax is equal to 20% of 
alternative minimum taxable income (generally, adjusted gross 
income plus items of tax preference)  in excess of exemption 
amounts. Taxpayers will be subject to the alternative minimum 
tax to the extent that it exceeds their regular tax. 
The alternative minimum tax is complex, and the impact 
of this new provision will depend on each individual's tax 
situation, including the amount of income subject to regular tax 
and the extent of other items of tax preference. 
For investors who will be subject to the alternative 
minimum tax, the tax benefits from R&D partnership deductions 
could be reduced to as little as two percent. Additionally, long-
term capital gains from R&D partnerships will continue to be 
items of tax preference  to the extent of the resulting capital gains 
deductions. Consequently, the tax reasons for investing in R&D 
partnerships will not apply to these individuals. For them, R&D 
partnerships must be simply good business investments, with 
any tax benefits simply an added feature. These investors will 
probably view royalty partnerships as undesirable, and view equi-
ty partnerships as little different  from any other conventional 
venture capital investment. 
With the passage of TEFRA, many people predicted that 
R&D partnerships would die out. As a matter of fact, the 
formation of privately-placed partnerships limited to a few large, 
tax-motivated investors has virtually disappeared. However, the 
growth of R&D partnerships is gaining new momentum with a 
slightly different  twist. Rather than large private placements 
requiring minimum investments of $50,000 or more, publicly 
placed partnerships requiring investments of as little as $5,000 
are becoming popular. Not only do these lower amounts make 
R&D partnerships available to a great many more investors, but 
they allow investors to arrange their investments at levels where 
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The first  step in any attempt to raise money is to develop 
a strategic business plan for your proposed project. The business 
plan will help you market your program and will serve as the foun-
dation for the agreements and other documents that must be 
drawn up. Just as important, the preparation of a business plan 
forces you to focus on what you are trying to accomplish and to 
analyze the costs involved. 
A well-conceived business plan3 is essential for an R&D 
partnership program. Your plan should include the following 
elements: 
• The project. Provide an extensive analysis of the R&D 
project. Identify the specific technology to be developed, 
the base technology that is available, and the personnel, 
facilities and equipment required to complete the project. 
• Technical feasibility. Decide whether the technology is 
possible, given the timeframe and budget you have es-
tablished. To help market a project, many companies have 
begun to use independent consultants or research firms 
(such as SRI International) to perform a technical evalua-
tion for them. 
• Market analysis. Estimate the potential demand for your 
product. What are the existing and potential markets? You 
should include assessments of your estimated revenues, 
your estimated production costs, the competition you 
may encounter, and the impact of alternate technology 
and obsolescence on the technology you will be develop-
ing. 
• Development plan. Prepare a detailed budget explaining 
the work to be done and the costs involved. Provide 
benchmarks for the completion of the project. 
3 Our first  Entrepreneur's Guidebook - Raising  Venture  Capital  - explains how to 
write an effective  business plan. 
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• Manufacturing and marketing plan. Once the project is 
completed, how will the new product be manufactured 
and marketed? Explain the costs of setting up 
manufacturing facilities, where the funds will come from, 
and what your marketing strategy will be. 
• Investment analysis. How will profits and losses be allo-
cated? What cash flow can investors expect? What tax 
consequences should they consider? 
Once your plan is completed, your next step will be to 
determine how you will market your program. 
Finding Investors 
Funding, probably the most difficult  task in the entire im-
plementation process, can be done through private placements 
or public offerings. 
If the amount of money to be raised is relatively small, you 
may be able to raise the funds yourself  through employees, 
friends, relatives, and other contacts. Alternatively, some attor-
neys and accountants will assist clients in organizing small (up 
to $500,000) R&D partnerships, not only to provide the clients 
with funds to conduct necessary R&D, but also to provide tax 
benefits to other clients of the law and accounting firms. If, 
however, the amount of money to be raised is relatively large, you 
should use an outside organization to help you locate investors. 
The marketing of R&D partnership interests is done by various or-
ganizations, from small "professional general partner" groups to 
the largest investment banking firms. 
Firms of so-called "professional general partners" have 
been popping up everywhere as R&D partnerships have become 
more popular. These firms are generally willing to take on pro-
jects to raise anywhere from $500,000 to $4,000,000 for compa-
nies in need of R&D funds. Some, such as Technology Funding, 
Inc. (San Mateo, CA), handle most of the technical matters neces-
sary to organize the partnership, but raise the capital through ar-
rangements with regional brokerage houses. Others, such as 
Alpha Fund (Palo Alto, CA) and Crosspoint Venture Partners (Palo 
Alto, CA), have blind pools already available for companies. R&D 
Funding Corp. (San Jose, CA) recently teamed up with Prudential 
Bache — while the former  screens projects and assists with the 
technical issues, the latter uses its retail brokerage network to 
raise blind pool funds. 
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Regional brokerage houses have been quite active 
recently in raising from $1,000,000 to $16,000,000 through R&D 
partnerships. Sutro & Co., Birr Wilson & Co., Inc., and Bateman 
Eichler, Hill Richards, among many others, have been pursuing 
R&D partnerships. Bateman Eichler raised its first  pool of R&D 
funds in November 1982 through a single R&D partnership to 
provide funding for four separate, unrelated public companies; it 
raised a second pool in December 1983 for five separate 
companies, four of which are publicly traded. 
National brokerage firms have also found R&D partner-
ships alluring. Merrill Lynch prefers  deals in the $25,000,000 to 
$60,000,000 range and up, although their recent Ventrex Tech-
nology Partnership was only a $15,000,000 program. E. F. Hutton, 
which boasts the largest tax shelter business among the major 
firms (some $700,000,000 in 1981), seems to prefer  smaller R&D 
deals in the $2,000,000 to $10,000,000 range. Oppenheimer & Co., 
which was one of the earliest explorers in R&D partnerships, now 
apparently prefers  programs of $20,000,000 or more. 
After your plan is developed and you have decided how 
and who will market your program, you can begin to have the 
agreements, other essential documents, and the offering  docu-
ment drawn up. The documentation process is complex, and you 
should use lawyers and accountants who have had prior 
experience with R&D partnerships. Many of the major law and 
accounting firms that serve high technology companies have 
experience in this area. 
Agreements 
R&D partnership arrangements must be carefully struc-
tured to insure that the intended tax benefits actually result and 
that both parties are adequately protected. R&D partnership ar-
rangements involve an array of agreements, all of which are 
generally executed concurrently. 
Limited Partnership Agreement 
The limited partnership agreement sets forth the terms 
and conditions of the partnership itself. It provides the terms for 
forming and dissolving the partnership; sets out the rights and 
obligations of the limited partners; and defines the rights, obliga-
tions, authority, and responsibility of the general partner. 
In those situations where the sponsoring company (or its 
subsidiary or affiliate)  is the general partner, the company faces 
49 
potential conflict-of-interest  problems. Management of the com-
pany has a responsibility to its shareholders; as the general part-
ner, it also has fiduciary responsibilities to the limited partners. 
Consequently, management may find itself in a position where it 
cannot satisfy both parties. The best solution may be to have an 
independent general partner. Companies reluctant to give up the 
general partner role can establish a partnership with two general 
partners - the company and an independent party. 
The partnership agreement provides for the allocation of 
profits and losses to the partners. Generally, almost all losses are 
allocated to the limited partners to the extent of their investment. 
Profits also are allocated almost entirely to limited partners until 
such partners have recouped their investment. Thereafter,  the 
general partner shares in profits. 
Base Technology Transfer  Agreement 
In most cases, the sponsoring company will already have 
completed some of the R&D work on the proposed technology. 
The creator or the sponsoring company must transfer  this base 
technology to the partnership. If the technology is well beyond 
the idea stage, the creator or sponsoring company may not want 
to transfer  all rights. To avoid doing so, the creator issues a base 
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Figure 5-1: Agreements and Other Essential Documents 
Investors 
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technology license to the partnership in exchange for a fee or a 
cross license of partnership-developed technology to the spon-
soring company. Generally, the license constitutes a non-exclu-
sive, worldwide, royalty-free  right to use for an indefinite term any 
know-how which the creator or sponsoring company owns with 
respect to the idea. 
If the sponsoring company decides not to buy out the 
partnership at the conclusion of the project, the partnership may 
want to sell or license the technology to another company. In cer-
tain arrangements, the partnership cannot do this unless it has a 
continuing license to the base technology. To protect the partner-
ship in these instances, agreements can include a clause stating 
that if the buy-out is not exercised, the company will license the 
base technology to the partnership at a specified fee or at its 
subsequent fair  market value (as determined by arbitration). 
Research and Development Contract 
Typically, the sponsoring company agrees to do the 
required research on a "best efforts"  basis. Contracts usually 
provide for payment of a fixed fee, or cost plus a fixed fee. This 
payment is equal to the total funds of the partnership, net of or-
ganization and promotion costs and working capital require-
ments. For tax purposes you should establish the contract as an 
arm's length transaction. To do this, the contract should provide 
some reasonable profit  to the company. The opportunity for the 
company to have preferential  rights to purchase the technology 
on completion of the work might be deemed sufficient  considera-
tion, but the provision of a normal profit  will give the arrangement 
the flavor of a genuine contract research agreement rather than 
an elaborate financing arrangement. 
Under the contract, the partnership agrees to pay the en-
tire R&D contract cost in advance or to make a substantial ad-
vance payment with the remainder to be paid in installments. 
These advance payments are the basis for early deductions for 
the limited partners. If the development period extends beyond a 
year, however, it may be difficult  to demonstrate a business pur-
pose for prepaying everything "up front."  In this case it would be 
more prudent to call for installment payments as the project 
progresses. 
The company should agree to expend all funds received 
from the partnership (other than its profit)  only for items deduct-
ible as R&D expenditures under Sec. 174. The general partner 
should monitor the expenditures periodically to satisfy its fidu-
ciary responsibilities to the limited partners. Initial IRS attacks 
on R&D partnerships have been to challenge the way the R&D 
company uses the funds rather than to challenge the partner-
ships on more technical grounds. 
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Under the contract, the partnership owns  the patent 
rights as well as all other technologies resulting from the 
development process. 
Developed Technology and Partnership Purchase Options 
Royalty partnerships and some equity-type partnerships 
give the sponsoring company an option to acquire the completed 
technology from the partnership, or the partnership interests 
from the partners, in exchange for royalties or a lump-sum buy-
out. Where the lump-sum buy-out is contemplated, the limited 
partner often has an option to take cash, stock in the sponsoring 
company, or both. It is important that the option to take stock 
rests with the partners or the partnership; otherwise, the IRS may 
apply the "disguised equity" doctrine (i.e.,  take the position that 
the original payments to the company were, in reality, for the pur-
chase of stock). In this case, the IRS would disallow the R&D de-
ductions previously taken. 
The royalty payments create a number of technical 
problems which should be considered in the purchase option 
itself. For example, there is the practical difficulty  of determining 
precisely which product sales should be subject to the royalty 
payment. Suppose the technology is later integrated into other 
products. Are sales of such future products subject to the royalty 
payment, and, if so, should there be some formula to segregate or 
apportion sales proceeds between a royalty element and a non-
royalty element? 
If partnership interests will be converted into stock of a 
new company, you may also face the "disguised equity" problem. 
The agreement should provide that the partnership interests can 
be converted only with a 2/3 affirmative  vote of the limited part-
ners. This requirement mitigates the appearance that the issu-
ance of stock is a foregone conclusion. 
Developed Technology License or Joint Venture 
Agreement 
In order for a royalty partnership to meet the holding pe-
riod requirements for long-term capital gains on the proceeds 
received from selling the technology or partnership interest to 
the sponsoring company, the partnership often must hold the 
technology for a year before the sale. So that the sponsoring 
company can use the technology immediately after development, 
the partnership allows the company to use it under a developed 
technology license agreement. Because of uncertainties as to 
when the holding period begins on developed technology, the 
period of the license should generally be for more than 12 
months. At the end of this period, the purchase option is exer-
cisable. 
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If the joint venture arrangement is used, a license 
agreement is generally not executed. 
Option to Acquire Stock 
Occasionally the partnership will be given warrants to 
purchase stock in the sponsoring company as part of the R&D 
contract. Many brokers will tell you that this is essential with 
some partnerships in order to market the limited partnership 
interests. Investors may need to have some "equity play" to 
entice them. 
Other Essential Documents 
In packaging an R&D partnership, there are various other 
documents which may need to be prepared. 
R&D Budget 
The reasonableness of the R&D budget is extremely im-
portant. If too much money is raised because the budget is 
excessive, the partnership risks loss of its R&D deduction. If too 
little is raised, the difficult  task of assessing partners or raising 
an unscheduled second round of financing, with attendant tax 
and logistics problems, comes into play. 
As a result, every R&D partnership must have an R&D 
budget that has been carefully prepared as part of the R&D con-
tract. This budget demonstrates to everyone how the partnership 
funds will be used and provides benchmarks on which the 
research can be evaluated. 
Project Feasibility Study 
Even sophisticated investors will find it difficult  to know 
whether the technology is feasible; whether the product can be 
manufactured on a commercially acceptable basis; or if manufac-
turable, whether the product can be marketed profitably.  This is 
particularly true of research and development in high technology 
areas. Accordingly, independent written reports by one or more 
reputable firms qualified to study such matters may be essential. 
Opinion of Patent Counsel 
If they can sell the technology pursuant to Sec. 1235, 
royalty partnerships may be able to achieve long-term capital 
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gains treatment without concern about the length of the holding 
period. To qualify, the technology must at least be patentable and 
should not be reduced to practice before the partnership's devel-
opment work commences. Even where Section 1235 doesn't 
apply, the "reduced to practice" issue is important in determin-
ing when the holding period starts. Essential documents for an 
R&D partnership should, therefore,  include the opinion of patent 
counsel as to patentability and the "reduced to practice" issue. 
Securities Opinion 
The company should also assure limited partners that the 
marketing of partnership units will comply with federal  and state 
securities laws. The documents of a well-organized R&D partner-
ship should therefore  include a securities opinion by knowledge-
able attorneys. 
Tax Opinion 
As in most investments of this type, investors should 
above all be confident that the venture makes good economic 
sense. Since the ultimate economic return, however, will in large 
part depend on whether the purported tax benefits will be real-
ized, the company should provide the investors with a detailed 
tax opinion by tax counsel or a CPA. 
Three areas are normally addressed in the tax opinion: 
• the classification for federal  income tax purposes of the 
limited partnership; 
• the deductibility for federal  income tax purposes of 
payments made by the partnership to the sponsoring 
company under an R&D contract; and 
• the character for federal  income tax purposes of pay-
ments, if any, received by the partners pursuant to a 
technology purchase agreement. 
Aware of the uncertainties surrounding these tax issues, 
many professionals are reluctant to give an opinion on them. 
Even when they do, their opinions must be couched in wording 
similar to the following: 
"We have advised the General Partner that, 
although the matter is not free from doubt, we 
believe that the federal  income tax benefits 
described are, in the aggregate, more likely than 
not to be realized by the investors." 
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Some opinions have been silent on the issue of the buy-
out, which is the most difficult  of the areas to structure properly. 
In these instances, investors may need to assume their proceeds 
will be taxed as ordinary income, and assess the offering  price 
accordingly. 
The Selling Document 
If you intend to publicly offer  partnership units for sale, 
you need to register with the SEC and prepare a prospectus. If 
yours will be a private placement (limited to 35 nonaccredited in-
vestors and an unlimited number of accredited investors4) you 
need not register with the SEC, but you may need to prepare a 
placement memorandum similar to a prospectus. 
The prospectus or placement memorandum is intended 
to provide potential investors with sufficient  information to 
assess the risks and merits of your offering. 
The typical document includes: 
• A description of the R&D activities to be performed. 
• The use of the proceeds.(Other than to pay the R&D con-
tract, proceeds might be used to pay underwriters' fees 
and organizational costs and to provide the partnership 
with some working capital.) 
• The significant risk factors. 
• The anticipated market for the products to be developed. 
• The anticipated competition. 
• Information about the sponsoring company, including 
financial data, descriptions of key personnel, experience 
related to the proposed project, etc. 
• A summary of the partnership and the partnership agree-
ment, including an explanation of the allocation of profits 
and losses. 
• Summaries of the R&D contract, base technology transfer 
agreement, developed technology or partnership pur-
chase option, license or joint venture agreement, and any 
other agreements and essential documents related to the 
R&D arrangement. 
4 Accredited investors are generally institutional investors, certain company 
insiders, and wealthy individuals. 
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• The tax opinion setting forth the probable tax conse-
quences of the potential transactions, e.g., the deduc-
tibility of costs and the tax treatment of any proceeds to 
the partnership. 
Often, the prospectus will also present the potential cash 
flows and taxable income to the limited partners if the project is 
successful. Accompanying this information is a set of 
assumptions used in preparing the projected amounts, so that 
investors can answer such questions as what their rate of return 
may be if sales are less than expected, if the project becomes 
delayed, etc. 
Ongoing Program Management 
The final stage of the financing program is ongoing man-
agement of the partnership. This task usually falls on the general 
partner who, as in other types of limited partnerships, is solely re-
sponsible for the management of the partnership. The general 
partner must monitor the progress of the R&D contract work, dis-
tribute royalties, and provide progress reports and tax informa-
tion to the limited partners. 
In some of the partnerships that have been offered  to 
date, an affiliate  of the sponsoring company has served as the 
general partner. However, there is a strong trend toward general 
partners that are completely independent of the company. An in-
dependent general partner protects the company from potential 
conflict-of-interest  problems and removes the partnership book-
keeping burden from management. 
The amount of time and effort  required to implement an 
R&D partnership financing program can be substantial and can 
divert significant management resources from the primary busi-
ness of the company. This time and effort  can be greatly reduced 
by utilizing investment bankers, R&D partnership service firms, 
accountants and lawyers with expertise in partnership financing. 
These experts can efficiently  accomplish the implementation 
tasks, so that your company can realize the full benefits of the 
R&D partnership program. 
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CASE STUDIES 
Syntex Diagnostic Limited 
Partnership 
Trilogy Computer Development 
Partners, Ltd. 
Genentech Clinical Partners, Ltd. 







R&D partnership arrangements have few limitations. They 
can be of any dollar amount. They can be sold privately or pub-
licly, locally or nation-wide. They can have royalty agreements, or 
they can have cash, equity, or cash-and-equity buy-out agree-
ments. To illustrate this flexibility, we present in this section ex-
amples of seven R&D partnerships which have been formed: 
• Syntex Diagnostic Limited Partnership — a private 
offering  to raise funds to develop five different  medical 
products for an established public company. 
• Trilogy Computer Development Partners, Ltd. - a public 
offering  to provide funds to a private start-up company. 
• Genentech Clinical Partners, Ltd. - a public offering  for an 
emerging public company, designed with a long-term 
joint venture arrangement. 
• Diversified Technology Partners, Ltd. - a public offering  to 
raise a pool of funds for four public companies. 
• Alpha Partners - a private offering  to provide seed money 
and, later, a second round of financing for a start-up 
company. 
• Beta Partners - a small private offering  to provide financ-
ing for a second product for an emerging private 
company. 
• Gamma Partners - a start-up company organized as a 
partnership. 
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Syntex Diagnostic Limited Partnership 
In November 1982, Syntex Corporation used an R&D part-
nership to raise funds for the development of five different  medi-
cal diagnostic products. 
Syntex is an international life sciences company that 
develops, manufactures and markets a wide range of health and 
personal care products. For fiscal 1982, its net income was $134 
million on sales of $813 million. Syntex medical diagnostic pro-
ducts, such as those to be developed using partnership funds, 
are developed and marketed through Syva Company, a wholly 
owned subsidiary. 
In the partnership prospectus, Syntex indicated that part-
nership funds would allow funding of more projects than other-
wise might be pursued because of financial considerations. Its 
R&D expenditures for fiscal 1982 were $84 million, or 10.3% of 
sales. 
Size of offering  — $23,500,000. 
Investment bankers — Allen & Company, Lehman Brothers Kuhn 
Loeb and Merrill Lynch White Weld Capital Markets Group. 
Minimum investment — $100,000, payable all in cash, or $8,300 in 
cash and the balance in a promissory note payable as follows: 
$28,500 in 1983, $23,300 in 1984, $31,200 in 1985, $5,300 in 1986 
and $3,400 in 1987. 
Net proceeds to partnership — $20,885,000 (net of placement 
fees of $1,645,000, financial advisory fees of $470,000 and offer-
ing expenses of $500,000). Upon consummation of the offering, 
the Partnership would borrow $2,583,000 from Syntex to pay sub-
stantially all fees and expenses related to the offering  and 
$2,000,000 from Merrill Lynch Interfunding for certain first-year 
research and development expenditures. The investor notes are 
pledged as collateral for these loans. 
Partnership agreement — benefits to be allocated 99% to the 
limited partners and 1% to the general partner. 
Cross license agreement — Syva provides the partnership with a 
limited, exclusive, worldwide license to use the base technology 
for the term of the development agreement and agrees to provide 
this license to any third party to which the partnership might 
transfer  the technology in the event that Syva does not exercise 
any of its options. In exchange, the partnership grants Syva a 
license to use the developed technology for purposes other than 
the five specific products to be developed by the partnership. 
Development agreement — Syva is to perform the research and 
development work for a fee allocated to the project as follows: 
Funding from the partnership: 
SQST Instrument and Module $ 2,200,000 
APRS Instrument 2,000,000 
Advance II Instrument 3,400,000 
Penicillin Dipstick Immunoassay Kit & Reader 4,200,000 
Blood Typing Kit and Instruments 7,450,000 
Total partnership funding 19,250,000 
Funding from Syntex: 
Blood Typing Kit and Instruments 4,100,000 
Total development fees $23,350,000 
Syva may reallocate funds among the projects, and excess funds 
on any completed project may be reallocated to other projects. 
Development fees allocated to the Blood Typing project total 
$11,550,000. The first  $3,350,000 of the project will be funded by 
the partnership. The remainder will be funded equally by the 
partnership and by Syntex. The funding from Syntex is in the form 
of a mandatory loan up to a maximum of $4,100,000. This loan will 
be repaid only if the Blood Typing project is successfully 
completed and only from partnership revenues attributable to the 
project. 
Syntex' total commitment under the mandatory loan is 
$4,600,000. Any amounts not lent to the Blood Typing project 
shall be made available, if necessary, to complete development 
of the other four projects. Repayment of such amounts is not 
dependent on successful completion of the projects. 
Interim license — During the periods between the completion of 
the projects and the dates the purchase options are exercisable, 
Syva may use the developed technology and products in return 
for royalties of 7-10%, depending on the product. 
Option agreements — Syva has an option to purchase the 
partnership's rights in the base technology and the developed 
technology of each of the five products. The options are 
exercisable between twelve and fifteen  months after the project 
completion dates. Purchase is in the form of royalties of 
generally 8% to 11%, depending on the product. For the Blood 
Typing product, royalties are payable until December 31, 2000 or 
until royalties equal $75,000,000, whichever occurs first.  For the 
other four products, royalties are payable for eight years, until 
December 31, 2000 or until royalties equal $75,000,000, whichever 
occurs first. 
The initial loans from Syntex and from Merrill Lynch 
Interfunding were made to facilitate cash flow in the early years 
of the projects, since the partnership units were payable in 
installments. 
Because this partnership encompasses five separate 
projects, the risk to the investors may be reduced — if any one 
project is unsuccessful, the investors can still look to four other 
projects for a potential return on their investment. 
Syva estimated that the risks associated with the Blood 
Typing project were substantially greater than the risks for the 
other projects, primarily because Syva had no experience in 
developing tests for the blood banking market and had limited 
marketing capabilities to reach that market. Consequently, the 
arrangement was structured so that Syntex shared that greater 
risk, up to a maximum of $4.1 million. 
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Trilogy Computer Development Partners, Ltd. 
Trilogy Limited is a Bermuda holding company, organized 
in September 1980. Trilogy Systems Corp. is its wholly-owned 
subsidiary, organized in August 1980. In August 1981, the com-
panies used an R&D partnership to raise funds to design a large 
scale, high performance,  general purpose computer system. 
The companies had no operating history — since forma-
tion, Trilogy Limited had engaged primarily in raising capital and 
organizing the corporate structure, and Trilogy Systems Corp. 
had engaged primarily in obtaining facilities and recruiting per-
sonnel to begin development of the computer design. In its pro-
spectus, Trilogy Limited estimated that it would be competing in 
a $7 billion market by 1985. 
Size of offering  - $55,000,000. 
Investment banker - Merrill Lynch White Weld Capital Markets 
Group. 
Minimum investment — $10,000 (2 units of $5,000 each). 
Net proceeds to partnership -
Limited partners' contribution $55,000,000 
General partner's contribution 555,556 
55,555,556 
Selling commissions and fees (3,850,000) 
Other expenses (641,000) 
Net proceeds $51,064,556 
Partnership agreement - profits and losses to be allocated 99% 
to the limited partners and 1% to the general partner. 
Technology license agreement - Trilogy Limited grants the 
partnership an exclusive, world-wide, royalty-free  license to use 
its base technology. 
Development contract - Trilogy Systems Corp. will perform the 
development work at cost plus a profit  varying from 0-15% of 
cost, as determined by a formula. 
License agreement - Trilogy Limited has the option, exercisable 
one year and one day after the technology is reduced to practice, 
to acquire an exclusive, worldwide license to use the computer 
design and sublicense it to others. The option does not expire un-
til 1988. Trilogy Limited will pay royalties of 7.7% to the limited 
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partners until payments equal $110 million, and thereafter, 
royalties of 3.3% or 11% of the pre-tax profits of Trilogy Limited, 
whichever is greater. Alternatively, Trilogy Limited may make a 
lump-sum payment equal to the greater of: (1) $220 million less 
royalties to date, or (2) $110 million. The partnership may elect to 
take 6,875,000 shares (as adjusted for a subsequent 4:1 stock 
split) of Trilogy Ltd. common stock in lieu of cash, or to take a 
combination of stock and cash. 
The buy-out option, if exercised by Trilogy Limited, allows 
the investor to take either cash or stock. The option for stock was 
given as an added inducement to the investors. The lump-sum 
buy-out declines over time to take into account any royalties paid 
in the interim. However, the number of shares which the partners 
may take in lieu of cash does not decline. If the project is suc-
cessful and Trilogy anticipates that the stock will be taken in lieu 
of cash, it would be to Trilogy's advantage to exercise its option 
as soon as possible to avoid the payment of royalties. 
At the time of the offering,  Trilogy Limited had 20,746,668 
shares of common stock and equivalents (convertible preferred) 
outstanding. Consequently, at the time of this offering  the 
partnership interests could be converted to a 25% equity interest 
in the company. 
In June 1983, additional funds for the project were raised 
through an equity offering.  In early 1984, in a move to prepare 
itself for raising still more funds for the project, Trilogy 
announced its intention to offer  to purchase the outstanding 
partnership units in exchange for Trilogy Ltd. common stock. The 
buy-out ratio of 625 shares per unit was the same as the stock 
buy-out ratio in the original purchase option agreement, so that 
the effective  cost to the limited partners for the stock received 
was $8 per share, less any tax benefits they derived from their 
initial investment. At the time Trilogy announced it would make 
the purchase offer,  its stock was trading at approximately $8 per 
share. 
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Genentech Clinical Partners, Ltd. 
In November 1982, Genentech, Inc. used an R&D partner-
ship to raise funds to clinically test and develop manufacturing 
processes and alternative delivery systems for human growth 
hormone ("hGH") and gamma interferon. 
The company has been in existence since 1976. Its main 
activity has been research and product development. During its 
development period, the company has tried to minimize its 
losses by covering operating expenses with revenue from re-
search and development contracts with customers. Under these 
contracts, the customers generally receive manufacturing and 
marketing rights in exchange for payments to Genentech for 
research costs and for royalties upon the ultimate sale of the 
products. 
In 1979, Genentech sold $10 million of preferred  stock; in 
1980, it sold $38 million of stock in an initial public offering;  and in 
1982, it sold $10 million more of equity. These funds were to be 
used primarily to acquire facilities and equipment and to fund 
working capital. 
Size of offering  - $55,000,000. 
Investment bankers - Blyth Eastman Paine Webber and 
Hambrecht & Quist. 
Minimum investment - $100,000 payable in five installments over 
3-1/2 years. 
Net proceeds to partnership -
Limited partners' contribution $55,000,000 
General partner's contribution 500,000 
55,500,000 
Selling commissions and fees (4,950,000) 
Other expenses (550,000) 
Net proceeds $50,000,000 
Partnership agreement - Profits and losses to be allocated 99% 
to the limited partners and 1% to the general partners. 
Cross license agreement - Genentech makes available its base 
technology in exchange for royalty-free  license to patents and 
know-how for all purposes other than use in the United States. 
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Development contract - Genentech will perform the development 
work at cost plus a retainer fee of up to $3,600,000. 
Option agreement - Upon FDA approval of the first  product, 
Genentech has the option to enter into a joint venture with the 
partnership to manufacture and market the products. The partner-
ship will receive 22% of the joint venture's profits and losses. Af-
ter the earlier of (a) four years or (b) two years and the allocation 
of $8.25 million of profits to the partnership, Genentech may pur-
chase the partnership interests. The purchase price will be 7% of 
sales until payments equal $55 million, then 5% of sales until 
payments equal $110 million, and 3% thereafter  until June 1998, 
with minimum royalties of $1 million per quarter for the first  12 
quarters. Genentech has the right to buy out the payment obliga-
tions for stock, cash, or other consideration, upon acceptance of 
the terms by 80% of the investors. 
In its business plan, Genentech projected that the joint 
venture would be formed in January 1984 and that sales of hGH 
and gamma interferon  would be $8.1 billion through June 1998. 
Note that Genentech has the option to purchase the partnership 
interests rather than the technology (as seen in earlier R&D 
arrangements). From a tax standpoint, practitioners have 
generally found buy-outs of partnership interests, rather than 
buy-outs of the technology, easier to qualify for long-term capital 
gains treatment. 
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Diversified Technology Partners, Ltd. - 1982 
Bateman Eichler, Hill Richards sponsored Diversified 
Technology Partners, Ltd. - 1982 to fund R&D projects for four 
separate publicly-held companies. The partnership's stated 
investment objectives were: 
(1)  To  return  Limited  Partners  at least  300% of  their  con-
tributed  capital  (exclusive  of  tax  benefits)  over  an 
eight  (8)  year  period 
(2)  To  generate  current  year  tax  deductions  to Limited 
Partners  in excess of  90% of  their  contributed  capital; 
and 
(3)  To  generate  royalty  income from  sale of  any  success-
fully  developed  partnership  technology,  substantially 
all  of  which  will  be eligible  for  long-term  capital  gains 
tax  treatment. 
Based on these objectives, the partnership selected the 
following four projects: 
1) Anderson Jacobson, Inc. 
Project: Voice/Data PBX System 
Revenues in last fiscal year: $50 million 
Product's potential for sale: $780 million through 1990 
2) Quixote Corporation 
Project: Laser videodisc mastering and replication 
process 
Revenues in last fiscal year: $20 million 
Product's potential for sale: $325 million through 1990 
3) Digilog, Inc. 
Project: Data line monitors/simulators 
Revenues in last fiscal year: $8 million 
Product's potential for sale: $150 million through 1990 
4) Velo-Bind, Incorporated 
Project: Proprietary Office  Product 
Revenues in last fiscal year: $19 million 
Product's potential for sale: $98 million through 1990 
Size of offering  - $16,650,000. 
Minimum Investment - $5,000. 
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Proceeds to partnership -
Limited Partners $16,650,000 
General Partner (a limited partnership, in which 
the four sponsoring companies are limited 
partners who have contributed $1,948,500; the 
general partner is an affiliate  of Bateman 
Elchler, Hill Richards) 1,948,500 
18,598,500 
Selling commission (1,332,000) 
Other expenses (766,500) 
Net $16,500,000 
Partnership agreement - profits,  losses, and cash distributions 
will be allocated before and after payout (receipt by the limited 




Before payout 95% 5% 
After payout 85% 15% 
License agreement - companies grant the partnership a royalty-
free non-exclusive license to use the base technology during the 
term of the R&D agreement. 
Development agreement - companies will perform the develop-
ment at cost plus a 10% profit  factor.  Contract prices are as 
follows: 









Option Agreements-The companies each have an option to enter 
into joint ventures with the partnership to manufacture and mar-
ket the new products. Joint venture profits will be split between 
the company and the partnership 80%-20%, respectively, for the 
first  14 months and 60%-40% thereafter.  The companies are 
committed to loan the joint venture up to the following amounts, 
as required by each joint venture: 
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If the companies exercise their joint venture option, they then 
have an option to purchase the technology 13 months after the 
first  product is shipped or the invention has been "reduced to 
practice." 
Royalties are payable for 10 years, on a graduated scale as 
follows: 
Anderson Jacobson: 8% reduced gradually until sales reach $766 
million, and 5% thereafter; 
Quixote: 20% reduced gradually until sales reach $162 million, 
and 2% thereafter; 
Digilog: 7% reduced gradually until sales reach $116 million, and 
2% thereafter; 
Velo-Bind: 9% reduced gradually until sales reach $47 million, 
and 2.5% thereafter. 
The pooled fund offered  many advantages to both the 
sponsoring companies and the investors. The companies prob-
ably could not individually sponsor R&D public offerings,  as the 
projects were not large enough and the companies not well-
known enough to make individual offerings  marketable. The 
investors have the advantage of diversification - their risk is 
spread among four separate projects. 
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Alpha Partners 
Immediately after Alpha, Inc. was established, the found-
ers formed an R&D partnership. Their intent was to use the part-
nership funds as seed money for the first  year of operations, 
primarily to complete development of a family of advanced 
computer systems. 
Round I 
Proceeds to partnership - Limited partners to contribute $800,000 
payable in installments over 8 months; general partner (Alpha, 
Inc.) to contribute base technology (valued at $13,000) plus 
$5,500. 
Development agreement - Alpha, Inc. will perform the required 
development work in exchange for $750,000. 
Partnership agreement - Profits to be allocated 37% to the gener-
al partner and 63% to the limited partners; losses to be allocated 
100% to the limited partners to the extent of their contributions, 
and thereafter  in accordance with the profits allocation. 
After  eight months, a second round of financing was 
sought. The company decided not to seek a different  source of 
financing. Instead, the partnership agreement was revised to 
admit two additional classes of partners. 
Round II 
Proceeds to partnership - $4,000,000 from Class B limited part-
ners and $1,000,000 from Class C limited partners, payable in 
installments over 13 months. 
Development agreement - Alpha, Inc. will perform the required 
development work in exchange for $4,000,000. 
Partnership agreement - Profits and losses to be allocated as 
follows: 
(1) R&D expenses - first  $750,000 to Class A (already 
spent and allocated); second $4,000,000 to Class B; 
third $50,000 to Class A again; and the remainder to 
the general partners. 
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(2) Other losses - first  $52,000: 96% to Class A, 1% to 
Class C, and 3% to general partner; second $52,000: 
96% to Class B, 1% to Class C, and 3% to general 
partner until Class B partners receive a total alloca-
tion of $4,000,000; thereafter,  1 % to Class C and 99% 
to general partner. 
(3) Profits:  44.10% to Class A, 23.08% to Class B, 6.92% 
to Class C and 25.90% to the general partner. 
In both arrangements, the contracts were silent as to the 
disposition of the technology. The partnership provides that it 
will incorporate at some point only if the incorporation is ap-
proved by 2/3 vote of the limited partners. Presumably, new 
shares will be issued based upon the partners' relative profit 
allocation. 
In Round II, the partnership sold a 30% interest for 
$5,000,000. The general partner's and the Class A partners' profit 
participation were reduced proportionately. The Class C partners 
were offshore  investors who had no need for U.S. tax deductions; 
consequently, allocations of losses to Class C partners were 
minimal (1% of residual losses). However, the Class C partners 
paid approximately 20% less for their investment than did the 
Class B partners. 
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Beta Partners 
Beta Company was founded in 1975. In July 1981, it had 
completed development of a major new product and was 
spending substantial amounts to develop its marketing network, 
install production equipment, and fund higher inventory and 
receivables levels. Beta Company had begun development on a 
second related product, and estimated that it would require 
$250,000 to complete that development. Although the company 
had access to a bank line of credit, the prime rate at that time was 
approximately 20%. Beta Partnership was formed to finance the 
remaining development. 
Proceeds to partnership - General partner (Beta Subsidiary) to 
contribute $2,500; limited partners to contribute $250,000 in two 
installments. 
Development agreement - Beta Company to develop the new 
product no later than October 1982 for $250,000. 
Partnership agreement - Losses to be allocated 99% to the 
limited partners and 1 % to the general partner until allocations to 
the partners equal $250,000. Thereafter,  losses to be allocated 
1 % to the limited partners and 99% to the general partner. All in-
come to be allocated 99% to the limited partners and 1% to the 
general partner. 
License and purchase option agreement - The company has the 
option to acquire an exclusive license for a maximum term of 14 
months in exchange for royalties of 10% of sales up to a maxi-
mum of $210,000. At the end of the license term, the company has 
an option to purchase the technology from the partnership for 
royalties of 10% of sales (subject annually to maximum cumula-
tive amounts and subject to an aggregate amount of $715,000) or 
a lump-sum payment. The lump-sum payment is based upon 
royalties paid through the date of the lump-sum payment and is 
also subject to a maximum of $715,000. 
The payments were designed to provide the investors 
with an annual 45% return on their net investment. For example, 
in the first  year, there was a maximum royalty payable of 
$210,000. In the second year, the maximum was $120,000 plus 
145% of any amount by which first-year  royalties were less than 
$210,000. 
The company found the project less difficult  than it had 
anticipated, and in January 1982 it was already contemplating 
how to consummate the buy-out. Beta Company had no cash, 
however, and began a few months later to negotiate an equity or 
equity plus cash buy-out with the investors. 
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The investors agreed to an early buy-out at a price that 
would provide them with a 45% after-tax rate of return. However, 
they were not interested in an equity buy-out unless the trans-
action could be structured as tax-free. 
The buy-out was structured as follows: 
(1) The partnership transferred  its technology to Beta 
Subsidiary in exchange for 26,993 shares of Beta Sub-
sidiary. The shares were valued at $229,000 and 
represented 20% of the outstanding stock as of 
November 1982 (the date of the buy-out). 
(2) Simultaneously, Beta Company transferred  a $125,000 
note to Beta Subsidiary in exchange for sufficient 
shares to bring its total shares held to 80% of the 
total. 
(3) Beta Company received a "cal l" option on Beta Sub-
sidiary stock which provided for the exchange of Beta 
Subsidiary stock for Beta Company stock on a one-
for-one basis. Similarly, the partners received a "put" 
option providing for the same exchange in case of 
certain events, such as a public offering. 
The transaction is designed to be a tax-free transfer  under 
Sec. 351, as immediately after the exchange, the parties transfer-
ring property (the prototypes and the note receivable) were in 
control (owned more than 80%) of the subsidiary. Beta 
Company's share of Beta Subsidiary was structured to be 80% of 
the total so that the company could consolidate the subsidiary 
for tax purposes. 
The result to the company of the R&D program was the 
receipt of $250,000 cash in exchange for the issuance of only 
$229,000 of stock sixteen months later! 
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Gamma Partners 
Gamma Partners was formed to develop and manufacture 
advanced communications products. The founder is the general 
partner and a venture capital group is the limited partner. 
Proceeds to partnership - The general partner to contribute all its 
right, title, and interest in and to any and all technology, know-
how, proprietary information, materials and products in respect 
of the communications product. Such contribution will have an 
agreed value equal to $11,000. 
Limited partner to contribute $110,000 initially for Phase I and to 
make additional contributions for subsequent phases, if and 
when certain milestones are satisfied. Total contributions will be 
as follows: 
Phase I - Prototype will be produced and market 
viability will be proven $110,000 
Phase II - Production and shipment will reach 
prescribed levels and field trials will be 
underway at three or more key customers 190,000 
Phase III - Management team will be in place; 
marketing, financial, and business development 
plans will be completed; and cumulative ship-
ments and a backlog will reach prescribed levels 370,000 
$670,000 
Partnership agreement - Losses to be allocated 99% to the 
limited partner and 1% to the general partner until the limited 
partner has been allocated aggregate losses in an amount equal 
to its capital contributions; thereafter,  in accordance with the 
profits allocation. Profits to be allocated as follows: 
During During During 
Phase I Phase II Phase III 
General Partner 75% 65% 55% 
Limited Partner 25% 35% 45% 
This arrangement reduces the risk for the investor. Rather 
than investing $670,000 all at once, the investor contributes in in-
crements. If the project does not progress as well as anticipated, 
the investor can walk away with a smaller loss. 
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In actuality, there will be no profits to allocate. But the 
profit  allocation shows how the limited partner's ownership in-
creases as he makes additional contributions. Based on those 
contributions, the company is assumed to be valued as follows: 
Phase I - $440,000 ($110,000 for a 25% ownership interest) 
Phase II - $1,900,000 ($190,000 for an additional 10% interest) 
Phase III - $3,700,000 ($370,000 for an additional 10% interest) 
After  Phase III was completed, the company incorporated 
and sold additional stock for its second round of financing, at 
which time the company was valued at $5,500,000. 
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APPENDIX I 
TAX CONSIDERATIONS FOR 
THE PARTNERSHIP 
The tax treatment of R&D partnerships is rife with uncer-
tainties. Many issues must be considered at the time the R&D 
arrangements are drafted in order to provide the most favorable 
tax treatment for the investors. Such issues include: 
• the structure of the partnership, 
• the deductibility of R&D expenses, 
• the deductibility of other partnership expenses, 
• the sale of the technology, and 
• the availability of research and experimentation credits. 
The Structure of the Partnership 
A number of issues not necessarily peculiar to R&D part-
nerships must be considered by all tax-oriented limited partner-
ships when designing the structure of their organizations. Many 
of these issues were raised by the IRS in rulings on whether 
certain partnerships could be classified for federal  income tax 
purposes as partnerships rather than associations taxable as 
corporations. 
In requests for advance rulings, the IRS has indicated that 
it will provide a favorable ruling if the following factors exist: 
• The limited partners own no more than 20% of the 
general partner, including ownership attributed under the 
rules of Code Sec. 318. 
• The general partner has at least a 1% interest in profits 
and losses of the partnership, not including any limited 
partnership interests that the general partner might hold. 
• Losses to the partners during the first  two years will not 
exceed the equity capital invested. 
• If the total capital of the R&D partnership is less than $2 
million, a sole corporate general partner has net worth 
equal to 15% of the total partnership capital or $250,000, 
whichever is less. (Net worth is computed based on the 
current fair  market value, rather than book value, of the 
general partner's assets, and excludes the general 
partner's investment in the limited partnership.) If the 
total R&D partnership capital is more than $2 million, the 
sole corporate general partner should have net worth, not 
including its partnership interest, equal to 10% of the 
R&D partnership capital. 
• The purchase of limited partnership interests in the R&D 
partnership does not include any purchase options (e.g., 
warrants) to acquire any type of security of the corporate 
general partner. 
• In the event the R&D partnership has nonrecourse credi-
tors, those creditors do not get an interest in the R&D 
partnership in exchange for the loan. 
The IRS will consider all of these factors in deciding 
whether to provide the partnership with a favorable ruling. If one 
or more of these factors does not exist, the IRS will probably not 
provide any ruling. The lack of a favorable ruling, however, will 
not necessarily preclude the partnership structure from 
producing the desired tax results for the partners. 
Deductibility of R&D Expenses 
Sec. 174 of the Internal Revenue Code of 1954 (the 
"Code"), as amended, provides that "a taxpayer may treat 
research and experimental expenditures which are paid or in-
curred by him during the year in connection with his trade or 
business as expenses" which are allowed as current deductions. 
Definition 
The partners' deductions depend on whether their funds 
are to be used for research and development. Unfortunately,  the 
Code and related Regulations provide only a little insight on the 
definition of R&D expenses. The regulations state that "research 
or experimental expenditures" include all research and develop-
ment costs (in the experimental or laboratory sense) incurred to 
develop an experimental or pilot model, a product, or an inven-
tion. The term also includes costs to improve an existing model, 
product, or invention.1 The costs of obtaining patents (e.g.,  legal 
fees), as well as the costs of perfecting title or defending the 
patent against attack, can also qualify under Sec. 174.2 Although 
the cost of capital equipment, other than supplies, does not 
qualify for R&D expense, depreciation of the equipment does.3 
A base technology transfer  or license agreement allows 
the R&D partnership to use this base technology in the R&D ef-
fort.  Payments to acquire title to the technology probably will not 
qualify for a deduction under Sec. 174, but periodic payments 
made under a technology license agreement are considered de-
ductible expenses under that provision. The base technology 
license must be carefully drafted. If the license term is too long 
(e.g.,  in excess of the useful life of the technology), the license 
payments may be characterized as expenditures to "acquire" 
technology. 
In addition, some expenses that are typically viewed as 
R&D costs in common parlance do not qualify for a deduction: 
• Cost for ordinary testing or inspection of materials or pro-
ducts for quality control do not qualify. However, testing 
and inspection costs incurred in building the prototype 
do qualify. 
• Efficiency  surveys. 
• Management studies. 
• Consumer surveys. 
• Advertising or promotions. 
• Cost of acquiring another's patent, model, production or 
process. 
• Research regarding literary, historical or similar projects. 
• Cost of land or depreciable property used in the R&D 
effort  (although the depreciation does qualify). 
1 Regs. Sec. 1.174-2(a)(1). 
2 Rev. Rul. 68-471, 1968-2 CB 109. 
3 Regs. Sec. 1.174-2(b)(1). 
81 
Because these costs are often incurred during the term of the 
R&D contract, they may mistakenly be treated for tax purposes as 
R&D expenses. Care must be taken to prevent the use of partner-
ship R&D funds for such expenditures. The research contract 
should specifically state that no partnership funds will be ex-
pended for any nondeductible R&D costs. If the partnership 
funds are the sponsoring company's only source of capital, these 
nondeductible items should be paid for with the profits from the 
R&D contract. 
When taxpayers do not acquire an ownership right in de-
preciable property and the property is used in connection with 
research and development, the entire cost  of the property is de-
ductible under Sec. 174. Therefore,  the R&D contract typically 
provides that the sponsoring company will acquire the required 
equipment and will also receive title to that equipment. As long 
as the R&D partnership has no ownership rights in the property, 
the partnership can deduct the amount of funds paid over to the 
company even if those funds are used to acquire equipment. The 
R&D contract should clearly state that all tangible assets 
acquired for the research belong to the sponsoring company. 
A more difficult  issue arises when the prototype is not 
built until all the abstract research and development has been 
completed. The regulations suggest that the actual costs of 
material, labor, etc., to build the prototype do not qualify for the 
Sec. 174 deduction.4 The partnership may have a stronger argu-
ment for deducting these costs if the R&D contract states that 
the prototype will belong to the sponsoring company and be 
leased by the partnership, although this approach has not yet 
been tested in court. 
Risk of and on Behalf of the Taxpayer 
To qualify for a Sec. 174 deduction, the research must be 
conducted at the risk of the partnership,5 and it must be per-
formed for the partnership's benefit. 6 
If the sponsoring company guarantees that it will produce 
the desired technology or product, the research is not considered 
as being conducted at the partnership's risk. If the company, 
however, guarantees that the research and development will be 
4 Regs. Sec. 1.174-2(b)(4). 
5 Regs. Sec. 1.174-2(b)(3). 
Regs. Sec. 1.174-2(c)(2). 
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performed pursuant to agreed specifications, the guarantee will 
not disqualify the R&D expenses, because the partnership still 
bears the risk for the overall results. 
Many developed technology purchase options require the 
sponsoring company to pay minimum royalties to the partnership 
in exchange for the technology, regardless of the success of the 
selling effort.  Some experts view minimum royalties as essential 
to insure that the sponsoring company makes a strong marketing 
effort.  Otherwise, the company may drop the new product in favor 
of a more profitable one. 
Minimum royalties may, however, be perceived by the IRS 
as reducing the partnership's risk. Consequently, they should be 
used with caution. Minimum royalties equal to a small 
percentage of the partners' capital investment may be 
permissible, as the partners would remain substantially at risk. 
But in most cases, even minimum royalties should be avoided if 
possible. Instead, the documents should be drafted to indicate 
that if the research is totally unsuccessful, the partnership will 
lose its entire investment in the research.7 
Cash vs. Accrual Basis Partnerships 
The Sec. 174 deduction is available to both cash and 
accrual basis partnerships. For tax purposes, most R&D partner-
ships use the cash basis of accounting. On this basis, partner-
ships can take deductions when a payment is made, provided 
that the payment is non-refundable except in cases of a breach of 
contract. 
The accrual method could accelerate the deductions of 
the limited partners, resulting in deductions in excess of the 
partners' actual out-of-pocket investment. 
Accrual basis partnerships are allowed the R&D 
deduction when the liability is fixed, i.e., when the R&D contract 
is signed. However, several requirements must be met before an 
accrual basis partnership can accrue a liability: 
• The liability must be legally binding and enforceable. 
• The liability cannot be contingent on some future event, 
such as performance  of other services by the sponsoring 
company. For example, the R&D contract cannot provide 
that the liability will be reduced or funds returned to the 
partnership if the sponsoring company is not able to 
reach certain contract milestones. 
7 For additional discussion of the "risk of taxpayer" requirement, see Rev. Rules 
73-275, 1973-1 CB 134, and 73-20, 1973-1 CB 133. 
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• The obligation must be certain in amount. 
• A substantial number of cases indicate that there must be 
reasonable belief on the part of the debtor that the liabil-
ity will be paid.8 Nevertheless, the structures of many 
"tax shelters" (including some R&D partnerships) imply 
that no one expects the accrued liabilities to be paid. For 
example, contract arrangements of many accrual basis 
R&D partnerships provide for the indebtedness to be paid 
from royalties. Under case law, these arrangements 
appear to lack sufficient  basis for accruing the liability. 
Sec. 465 of the Code limits the partners' deductions to 
the amount the partners are at risk at the end of the partnership's 
fiscal year. Accordingly, for accrued expenses to be deductible, 
partners must also be personally liable under the R&D contract. 
When the partnership is formed, the limited partners 
should give full recourse notes to the partnership in an amount 
equal to the additional contributions the limited partners are 
obligated to make to pay off  the accrued expenses. Requiring the 
partners to also provide back-up letters of credit adds substance 
to the recourse note arrangement. Ideally, the partners should 
pay off  their notes within a short period of time; otherwise, the 
IRS may question the need for these amounts for R&D. 
Arrangements which call for recourse notes with maturity dates 
several years into the future or beyond the anticipated 
completion date of the R&D project should not be used. Instead, 
the sponsoring company could borrow against the notes to 
obtain the funds for the research. However, most commercial 
lenders are not willing to extend credit on this basis. 
A cash basis partnership could also provide its partners 
with deductions in excess of the partners' investment if the part-
nership rather than the company borrowed against the partners' 
notes and then gave the proceeds to the sponsoring company. A 
recent Merrill Lynch partnership, Ventrex, used this approach. 
But Merrill Lynch, rather than a more conventional commercial 
lender, loaned the funds to the partnership. 
Prepayment of R&D Contract Costs 
Prepayment of R&D contract costs by a cash-basis 
partnership allows the limited partners to obtain "up-front" 
deductions. That is, the partners can obtain deductions before 
any substantial amount of research under the contract has taken 
place. The deductions are available in the year of the investment, 
even if the investment is not made until very late in that year. 
8 See, e.g., Putoma Corp., 66 TC 652 (1976); United Control Corp., 38 TC 957 (1962), 
acq., 1966-1 CB 3; Dixie Pine Products Co., 320 US 516 (1944) (31 AFTR 956, 44-1 
USTC para. 9217). 
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Rulings on expenses other than research and develop-
ment (e.g.,  prepaid fee deductions) indicate that a prepaid 
expense must meet several requirements before it can be deduct-
ible by a cash-basis taxpayer: 
• The prepayment may not be a deposit. To prevent the 
prepayment from being classified as a deposit, the R&D 
contract must specifically require that prepayment be 
made to the sponsoring company before any services are 
rendered.9 To avoid any inference that such payment is 
contingent, the contract should also state that the obliga-
tion to pay is independent of the obligation to perform 
services. Further, the prepayment must be nonrefund-
able, except for a material breach of the contract. 
• The prepayment must have a business purpose. A number 
of good business reasons may favor prepayment of the 
contract fee. For example, most contract R&D firms will 
not grant credit to a new company with an untried process 
or product idea. If the sponsoring company is a new en-
terprise, the funds from the R&D partnership may con-
stitute its only source of capital. Likewise, the company 
may need to hire several skilled personnel to fulfill  the 
contract. These people may need assurance that they will 
be employed for a certain length of time and that the 
funds to compensate them are currently available. Simi-
larly, vendors may need assurance that they will be paid 
before they agree to deliver materials and equipment 
crucial to the project. Prepayment also allows the R&D 
company to order materials in efficient  quantities. 
• The prepayment must not result in a material distortion of 
income. The "distortion of income" test is not trouble-
some for R&D partnerships, because Sec. 174 expenses 
are exempt from the capitalization requirement of Sec. 
263. In addition, R&D costs appear to resemble product 
costs more closely than the period costs (such as prepaid 
rent or prepaid insurance) to which the distortion of in-
come test is usually applied. Nonetheless, cash-basis 
partnerships should not prepay R&D costs for a period of 
work in excess of one year. 
The Zaninovich  rul ing 10 sanctions the current deduction 
9 George Cheroff,  TC Memo 1980-125. 
10 Martin J. Zaninovich, 616 F2d 429 (9th Cir. 1980) (45 AFTR2d 80-1442, 80-1 USTC 
para. 9342). 
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of prepayments not covering periods in excess of one 
year, and provides the partnership with additional support 
for a current deduction. There is also a practical reason 
for making payments in installments — the general 
partner can monitor the project's progress before making 
the next payment and thereby have some additional 
leverage over the sponsoring company. 
In early 1984, legislation was proposed to prohibit a part-
ner in a cash basis partnership from taking a current deduction 
for payments under a development contract until the develop-
ment is actually performed by the company. If the legislation is 
enacted, it will preclude the deduction for prepaid development 
expenses for a partner in a cash basis partnership. 
Reimbursement of Pre-contract Costs 
Partnership organizers frequently incur expenses before 
any contract is signed with the sponsoring company, and then 
seek reimbursement from the partnership. For the partnership to 
get a deduction under Sec. 174, the pre-contract work must be 
performed on the partnership's behalf and at its risk. 
If substantial R&D work took place before formation of 
the partnership and execution of the R&D contract, the 
partnership should license  the work from the person who 
conducted the research, rather than reimburse the individual for 
the costs, because this pre-contract work may not be viewed as 
performed "on behalf of the partnership." The license fee should 
be deductible if: (1) the partnership's use of the technology is 
limited to the purpose and duration of the partnership effort;  and 
(2) the partnership does not acquire ownership of the technology. 
Where only a little pre-contract work occurs before the 
formation of the partnership, most practitioners believe that 
reimbursed expenses can be deductible under Sec. 174. 
Practitioners hope that a de minimis  rule will permit these 
deductions, although there is no statutory basis for this 
conclusion. 
Pre-contract costs incurred after  formation of the partner-
ship can be reimbursed on a deductible basis, as provided for in 
the partnership agreement. Pre-contract work may begin, based 
on the understanding that the partnership will raise the money to 
reimburse these costs. 
Regardless of the arrangements for reimbursement of 
these costs, the following tax issues must be considered: 
• Do the costs represent true R&D costs or costs to 
purchase technology? 
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• Was the work performed on the partnership's behalf and 
at its risk? 
• Did pre-contract work produce anything that was 
"reduced to practice" before the partnership was finally 
organized?11 
In early 1984, legislation was proposed to prohibit a 
partner in a cash basis partnership from taking a current 
deduction for reimbursement of costs, if those costs were 
incurred prior to the partner's admission to the partnership. If this 
legislation is enacted, payments made by a partnership would be 
allocated to partners based upon when the partners were 
admitted to the partnership. 
Software Development Costs as Qualifying R&D 
Expenditures 
The IRS has never concluded that software development 
costs are R&D costs, but a 1969 ruling states that software 
development costs are deductible under rules which are "similar 
to" Sec. 174 expenditures.12 Several recent private letter rulings 
treated software development costs as Sec. 174 expenses, while 
continuing to refer  to them a "similar to" Sec. 174 deductions.13 
In 1983, the IRS issued proposed regulations under Sec. 
174 which stated that the costs of developing computer software 
were not research or experimentation expenditures within the 
meaning of Sec. 174 if the operational feasibility of the software 
in question were "not seriously in doubt." This proposed 
regulation was issued simultaneously with and as a clarification 
of the expenditures which qualified for the calculation of the Sec. 
44F tax credit for research and experimentation. After  the 
issuance of these proposed regulations, the IRS announced that 
the rules on deductibility as set out in Rev. Proc. 69-21 would not 
be superseded by the proposed regulations.14 Consequently, 
software development costs that do not meet the criteria of 
doubtful operational feasibility do not qualify as R&D 
expenditures for purposes of Sec. 44F, but may qualify as R&D 
expenditures that are currently deductible under Rev. Proc. 
69-21. 
1 1 This "reduced to practice" issue affects  both whether the partnership can 
deduct the costs under Sec. 174 and whether the partnership can ultimately 
realize long-term capital gains under Sec. 1235. 
1 2 Rev. Proc. 69-21, 1969-2 CB 303. 
1 3 See, e.g., IRS Letter Ruling 8136024 (TAM, 5/27/81). 
1 4 Announcement 83-83, 1983-19 IRB 66. 
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The Alternative Minimum Tax Problem 
Under the Tax Equity and Fiscal Responsibility Act of 
1982 (TEFRA), individual investors who elect to currently deduct 
research and experimentation expenditures under Sec. 174 must 
include 90% of such deductions as tax preference  items subject 
to the alternative minimum tax.1 5 Under Sec. 58(i), the preference 
item can be avoided by an election to amortize the prepaid R&D 
deduction over ten years. However, this strategy would defeat the 
tax purpose of the partnership. 
The impact of the alternative minimum tax will be depen-
dent on each taxpayer's circumstances. For tax-oriented in-
vestors already subject to alternative tax, the net tax benefit from 
R&D partnership investments may be negligible (at worse, the in-
vestments would generate only a 2% tax deduction). Con-
sequently, the potential returns may not be sufficient  to induce 
the taxpayer to invest. Each taxpayer must evaluate his or her 
own tax position and determine whether, after consideration of 
the alternative minimum tax, the investment return is adequate. 
Deducting Other R&D Partnership Expenses 
Warrants 
Under some R&D contract arrangements, the partnership 
receives warrants for stock in the sponsoring company, presum-
ably to encourage investment. The IRS will probably try to re-
classify a portion of the amount paid under the R&D contract as a 
cost to purchase the warrants, rather than as R&D expense. The 
value of the warrants will depend upon the maturity of the com-
pany and the particular circumstances in each instance. Practi-
tioners should consider this issue at the outset, making apropri-
ate allocations in the documents rather than risking an allocation 
by the IRS in a later examination. 
Administration Fees 
Administration fees paid to the general partner and reim-
bursement of the general partner's out-of-pocket costs should be 
deductible as Sec. 162 deductions, as long as the partnership is 
conducting a trade or business. (See the discussion of this "trade 
or business" requirement on page 89.) 
Organization Costs 
Costs incurred for the actual formation of the partnership, 
including the drafting of the partnership agreement and the 
various filing fees, must be capitalized. However, the costs can 
be amortized over 60 months.16 
1 5 TEFRA adds Sec. 57(a)(6) which treats R&D expenditures as a tax preference 




Syndication costs are those incurred in the sale of part-
nership units, including: the legal, accounting, and consulting 
fees related to the offering;  the cost of producing the prospectus; 
and any commission paid on sale of the units. Fees for advice 
pertaining to the adequacy of the tax disclosures in the prospec-
tus are also considered syndication costs.17 Syndication costs 
must be capitalized and may not be amortized.18 
Tax Advice 
Fees paid for advice on the income tax consequences 
from operation of the partnership are deductible under Sec. 
212(3) when paid. Expenses incurred in connection with the 
realization and monitoring of royalty income, including general 
and administrative expenses, are deductible under Sec. 162(5). 
Start-up Costs 
Start-up costs, which are defined as expenditures for 
initial activities before the actual commencement of "business," 
may, at the partnership's election, be amortized over not less 
than 60 months from the date business begins.19 
The "Trade or Business" Problem 
The IRS may contend that many partnership expenses, 
otherwise deductible under Sec. 162, should be capitalized 
because the partnership is not "carrying on a trade or business." 
Although you could argue that the partnership's business begins 
when research is started, the IRS approach has been to deny the 
"carrying on a trade or business" status until income has been 
realized or some product offered  for sale.20 
Complicating matters, the House Committee Report to 
Sec. 221 of ERTA regarding the research and experimentation 
credit states, "Receipt of royalties does not constitute a trade or 
business under present l aw . . . . In such a case, the nexus 
between the research and the transferee's  activities generally 
would be insufficient  to support a finding that the taxpayer had 
1 7 Prop. Regs. Sec. 1.709-2(b). 
18 Sec. 709(a). 
19 Sec. 195(a). 
20 Rev. Rul. 81-150, 1981-1 CB 119. 
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incurred the research expenditures in carrying on a trade or 
business."2 1 Under this rationale, a typical royalty R&D 
partnership may never be viewed as carrying on a trade or 
business, and an equity partnership may not be viewed as 
carrying on a trade or business until it begins to realize income or 
ships the product. (The report goes on to say that "under 
appropriate circumstances, nevertheless, the nexus might be 
deemed adequate for purposes of the Sec. 174 deduction.") 
Some practitioners recommend that the sponsoring 
company or a partner or joint venturer transfer  some product to 
the partnership so that the partnership qualifies as "carrying on a 
trade or business" from the outset. The problem is also avoided 
when a joint venture is formed with the sponsoring company to 
manufacture and market the product. 
If the IRS successfully argues that an R&D partnership's 
non-R&D expenses cannot be deducted as Sec. 162 expenses be-
cause of the trade or business requirement, these expenditures 
could probably be treated as start-up costs to be capitalized and 
amortized over 60 months from the date business begins. If start-
up costs are to be amortized, the partnership must make an 
election to do so at the time its first  tax return is filed. 
Sale Of The Technology 
One of the goals of many R&D partnerships is to enable 
the investors to recognize the ultimate sale of the technology as 
long-term capital gains. Various techniques enable the partner-
ship to do this. 
Section 1235 
The sponsoring company will usually want to buy the 
completed technology as soon as it has been developed, as the 
company generally wants to control the technology as soon as it 
can do so. Sec. 1235 permits the transfer  of the technology to the 
sponsoring company with any gains treated as long-term  capital 
gains, even if the partnership has only held that completed tech-
nology for a short period. This long-term capital gains treatment 
is automatic, as Sec. 1235 confers capital asset status with no 
holding-period requirements. In addition, the entire gain is 
treated as long-term capital gain even when the consideration is 
payable over time (e.g.,  as in the instance of royalties), thus avoid-
ing the imputed interest rules of Sec. 483. (Sec. 483 is discussed 
on page 97.) 
2 1 House Committee Report on H.R. 4242, 97 t h Cong., 1st Sess. (1981). 
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Although Sec. 1235 is often thought to confer a tax 
benefit on patented  technology, it also applies to technology that 
is patentable.  There is no need for an actual patent or even an 
application.22 This is a critical consideration for many high tech-
nology companies, which are often unwilling to make the public 
disclosures required to obtain a patent. 
To qualify for capital gains treatment under Sec. 1235, 
there must be a transfer  of "all substantial rights." The provision 
will not apply to a sale of patentable technology rights by the 
partnership if the rights sold are limited geographically (e.g., 
within the country of origin) or in duration (e.g.,  to a period less 
than the remaining life of the patent or useful life of the underly-
ing technology). Similarly, Sec. 1235 will not apply if the sponsor-
ing company (or anyone else) purchases the technology from the 
partnership under an agreement that (1) limits the company to 
less than all the claims and inventions covered by the patent, or 
(2) limits the use of the patent or patentable technology to fields 
of use within specified trades or industries covering less than all 
the existing and valuable r ights. 23 In addition, the transfer  of 
rights must include the right to use, make and sell the patented 
or patentable article or device.24 
In summary, to satisfy the "al l substantial rights" test, 
the agreement transferring  the technology should provide for the 
transfer  of all rights to use, manufacture, and sell the product or 
products throughout the world during the period of the 
technology's useful life, and the ability to prevent disclosures, 
including any disclosures by the R&D partnership itself, of the 
technology to unauthorized persons. 
The partnership may want to retain a security interest in 
the transferred  technology to protect itself against the sponsor-
ing company's failure to pay royalties or to make note payments. 
This will not invalidate the use of Sec. 1235, as a security interest 
is not viewed as a substantial right for this purpose.25 
In many situations, the developed technology may be 
2 2 Regs. Sec. 1.1235-2(a) suggests that the technology can be patentable for Sec. 
1235 to apply, since a patent or patent application need not exist. See Max A. 
Burde, 352 F2d 995 (2d Cir. 1965) (16 AFTR2d 5885, 65-2 USTC para. 9733), cert. 
denied 383 US 966 (1966); F.H. Philbrick, 27 TC 346 (1956). 
2 3 Regs. Sec. 1.1235-2(b). 
2 4 Taylor-Winfield Corp., 476 F2d 483 (6th Cir. 1972) (30 AFTR2d 72-5711, 73-1 
USTC para. 9113). 
25 Regs. Sec. 1.1235-2(b)(2)(ii). 
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partly patentable and partly nonpatentable. For example, a com-
puter may be patentable, but the software that allows it to 
operate is not. When the sales contract does not include an 
allocation, the IRS will attempt to allocate some consideration to 
nonpatentable technology to disallow Sec. 1235 treatment for 
that portion of the sale. Contracts should therefore  allocate the 
purchase price between patentable and nonpatentable 
technology. The patentable technology can be sold immediately, 
resulting in long-term capital gains treatment under Sec. 1235. 
The nonpatentable technology can be licensed to the sponsoring 
company and sold when the holding-period requirements have 
been satisfied. 
In addition to the "all substantial rights" requirement, 
Sec. 1235 applies only to sales of patentable technology by a 
"holder." Sec. 1235 defines a holder as an individual  who created 
the technology or acquired an interest in the technology from the 
creator in exchange for consideration paid in money or money's 
worth. 26 
A corporation is not an "individual," and therefore  cannot 
qualify as a "holder." Similarly, an R&D partnership does not 
qualify as a "holder"; however, the regulations apply a "look 
through" approach, and allow individual partners to qualify for 
Sec. 1235 treatment 2 7 Corporate partners in an R&D partnership 
do not qualify. 
Under the definition of "holder," the individual partners of 
the R&D partnership will qualify for capital gains treatment only if 
the partnership acquires the patentable property from the creator 
for consideration in money or money's worth. Usually, the R&D 
partnership will give the creator a partnership interest in ex-
change for the base technology, and this interest constitutes 
"money's worth." Alternatively, the partnership may make a di-
rect payment of a fixed sum to the creator or provide the creator 
with property to use in developing the technology.28 Where the 
creator is not a partner, some practitioners recommend that each 
partner (rather than the partnership) pay something directly to the 
creator. Regardless of the approach selected, the payment for 
the purchase of base technology cannot be deducted by the 
partnership. 
26 Sec. 1235(b). 
27 Regs. Sec. 1.1235-2(d)(2). 
28 Regs. Sec. 1.1235-2(d)(2). 
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The base technology will often be developed by an em-
ployee of a corporation. The corporate employer of the inventor at 
the time the technology is transferred  to the partnership does not 
qualify as a "holder." 2 9 Frequently, however, the employee will 
have given up all rights to the invention under his or her employ-
ment contract. In order to give the R&D partnership an oppor-
tunity to use Sec. 1235 in this situation, the corporate employer 
must release the creator from any obligations under the employ-
ment contract and transfer  any rights in the base technology 
back to the creator. The creator can then assign his or her patent 
rights to the partnership in exchange for money or money's 
worth. 
Partners also cannot qualify if they are related to the 
creator/inventor. A related person for purposes of Sec. 1235 is a 
family member, such as a grandparent, parent or child. However, 
brothers or sisters don't count as family members for this 
purpose.30 
Additionally, the partner cannot qualify if the partnership 
sells the technology to a "related" corporation. The partner and 
partnership will not be considered related to the corporation so 
long as they do not own, directly or indirectly, 25% or more of the 
corporation's stock. For this purpose, stock owned by a partner-
ship is considered to be owned proportionately by its partners, 
and any partner owning stock in a corporation is deemed to 
also own the stock owned by the other partners. Accordingly, the 
related corporation rule should not create a problem as long as 
all partners in the R&D partnership own less than 25% of the 
sponsoring company. However, if partners, in the aggregate, own 
more than 25% of the company, all partners owning any stock in 
the sponsoring company will be disqualified as "holders" be-
cause they will be treated as related to the company, as will the 
inventor/creator if that person is also a partner. 
If the R&D partnership itself has a stock interest in the 
sponsoring company, the partners will be viewed as owning what 
the partnership owns for purposes of the 25% test. In most R&D 
partnership arrangements the R&D partnership does not own any 
stock in the company. However, R&D partnerships and/or part-
ners do sometimes receive warrants in the company. It is not 
clear whether these warrants constitute a stock interest which 
could disqualify the partners as "holders." 
R&D partnerships sometimes need a second infusion of 
capital from new and different  partners to fund the completion of 
the R&D work. Careful  planning may be necessary so that these 
2 9 Sec. 1235(b)(2)(A). 
3 0 Regs. Sec. 1.1235-2(f)(1). 
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new partners can also qualify as "holders." For purposes of Sec. 
1235, the original partners acquired the base technology from the 
creator, but the new partners must also acquire the technology 
from the creator to qualify under that provision. One solution is to 
hold open the assignment of the inventor/creator's rights, and 
have each new partner make some payment directly to the 
inventor/creator. 31 The problem can be avoided, however, if the 
inventor/creator is named the general partner in the R&D partner-
ship. With this approach, when the new limited partners 
purchase their interests in the partnership, those interests are 
considered to be purchased from the creator/general partner. 
Sections 1221-1223 and Section 1231 
Because of the stringent requirements of Sec. 1235, many 
R&D partnerships must rely on other sections of the Code to ob-
tain long-term capital gains treatment on sale of the developed 
technology to the sponsoring company. Sections 1221-1223 
(which deal with the sale of capital assets) and Sec. 1231 (which 
deals with the sale of property used in a trade or business) may 
provide the bases for this treatment. 
A capital asset is defined in Sec. 1221 as property which 
is (1) not held for sale to customers and (2) not used in a trade or 
business and subject to depreciation. Depreciable or amortizable 
property used in a trade or business that has been held for more 
than one year after reduction to practice can qualify for capital 
gains treatment under Sec. 1231. Copyrights, letters, memoranda 
or similar property created by the taxpayer are ineligible for 
capital gains treatment under either Secs. 1221 or 1231. 
Reliance on Secs. 1221 or 1231 for capital gains treatment 
involves three main issues: (1) whether a sale or exchange has 
occurred; (2) whether the developed technology qualifies as a 
capital asset (or property); and (3) whether the technology has 
been held long enough by the partnership to qualify for long-term 
capital gains treatment upon sale to the sponsoring company. 
Occurrence of a sale or exchange. A base technology 
transfer  agreement provides the partnership with the right to use 
the sponsoring company's technology within a specified field 
and territory. Occasionally (most often with established 
companies), the agreement will also provide that any partnership-
developed technology may be used by the sponsoring company 
outside the specific territory and field of use. This provision 
assists in sustaining that the original transfer  of technology 
should be a royalty-free  license without any recharacterization of 
3 1 See, e.g., Donald, 228-2d T.M., Patent Transfers  - Sec. 1235, at 4-7. 
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the development fees as payment for previously developed 
technology. It also allows the sponsoring company to use 
portions of the technology for other products which are not being 
funded by the partnership. 
Under such an agreement, however, the IRS might argue 
that, although the partnership transferred  all of the rights which it 
had in the technology at the time it sold the technology to the 
company, the partnership may not be selling all of the substantial 
rights which it ever had in the property. If this argument could be 
sustained, then the payments received for the technology would 
be ordinary income as there would be no sale or exchange. 
Qualifying as a capital asset. In considering whether the 
technology is a capital asset, two subsidiary issues may be 
involved: the tax benefit rule and the exclusion of inventory from 
the definition of capital assets. 
In 1984, the IRS, in a technical advice memorandum32, 
applied the tax benefit rule to determine that a company was 
required to recognize the proceeds from the sale of patents and 
secret technology as ordinary income to the extent that 
expenditures attributable to the development of the property 
were taken as an ordinary deduction under Section 174(a). Citing 
the Hillsboro  National  Bank  case3 3 as authority, the IRS 
contended that to classify the gain on a subsequent sale of 
technology as solely capital gain was fundamentally inconsistent 
with the earlier development deductions. Thus, only the gain in 
excess of the 174(a) expenses could be eligible for capital gains 
rates. Although expectations are that the IRS position will 
ultimately be challenged and final determination made in the 
courts, practitioners should be aware that the IRS will attempt to 
use the tax benefit rule to classify a portion of the sale proceeds 
as ordinary income. Selling the partnership interests (which is 
discussed on page 99) may be one alternative for avoiding the tax 
benefit rule issue. 
The more difficult  problem in achieving capital asset 
status for the technology stems from the Sec. 1221 definition of 
capital assets. Inventory is excluded from this definition, and, 
therefore,  the sale of inventory produces ordinary income regard-
less of the holding period. R&D partnerships may have difficulty 
in establishing that the technology is not inventory. Since the 
partnership may never be in a position to manufacture, market, 
and sell a product, the IRS may view the sale of the technology 
32 IRS Letter Ruling 8409009. 
33 Hillsboro National Bank, 130 US 1134 (1983) (51 AFTR2d 83-874, 83-1 USTC para 
9229). 
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itself as a foregone conclusion. Further, if the sponsoring com-
pany has an option "up front" to purchase the technology as part 
of the R&D contract, the contention that the technology is inven-
tory seems stronger. 
The partnership may be more successful in establishing 
that the technology is a capital asset if it can characterize the 
partnership as a product-oriented rather than a technology-
oriented organization. The partnership can argue that it must rely 
on sales of the ultimate product rather than the sale of the tech-
nology for its revenue. A royalty arrangement based on sales 
would bolster this argument more effectively  than either a lump-
sum payment for the purchase or a requirement for substantial 
minimum royalties, since the royalty arrangement suggests that 
the R&D partnership is product-oriented. 
To meet the holding period requirements discussed be-
low, the partnership must license the technology to the sponsor-
ing company before the sale. By closely monitoring the product 
during the license period, the partnership may strengthen its 
claim to being a product-oriented venture. Although it is gener-
ally impractical to do so (especially in high technology), the part-
nership may want to license the technology to more than one 
licensee until the technology is sold. 
The use of a joint venture arrangement with the 
sponsoring company to manufacture and market the product 
strengthens significantly the partnership's argument that it is a 
product-oriented venture. This is because the partnership must 
rely on net income from joint venture operations rather than sales 
by the sponsoring company. 
The type of purchase option given the sponsoring 
company is a critical factor in determining whether the 
technology is inventory. The option must be a true option, with 
the real possibility that the company may not exercise it. If the 
terms of the arrangement, the surrounding circumstances, or 
good business practice can compel the exercise of the option, 
the likelihood of capital asset treatment will be reduced. Most 
partnerships require an upfront nonrefundable cash payment 
upon the exercise of the purchase option. 
Holding period. If the technology qualifies as a capital 
asset, the partnership must demonstrate that it has met the 
twelve-month holding period when the technology is sold. The 
partnership's holding period starts when the technology has 
been "reduced to practice." Therefore,  the technology must be 
leased or licensed to the user, or a joint venture must be 
established, for a period equal to the required long-term holding 
period. The lease or license period should actually be longer than 
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the required holding period because of uncertainty as to when 
the technology has been "reduced to practice." The best 
approach is to obtain a patent counsel's opinion on when the 
technology has been reduced to practice and then license or joint 
venture it for 14 to 16 months thereafter. 
Any option to acquire the technology granted by the 
partnership should not be exercisable until the license or joint 
venture period has expired. The option should again be a true 
option; otherwise the IRS may treat the arrangement as an 
installment sale. The Supreme Court has held that when property 
is leased or licensed, the property is deemed sold when the 
option is exercised, rather than when the lease or license is 
entered into.3 4 However, if the lease or license arrangement is 
essentially an installment sale contract, the technology will be 
deemed sold when the contract is made.35 For the R&D 
partnership, this would mean a sale without a sufficient  holding 
period. 
To create the strongest case for true license or joint 
venture treatment, the partnership should follow the basic rules 
for operating leases. License fees or joint venture income should 
not be applied to the option price. If a license is used, it should be 
non-exclusive to avoid an argument that substantially all rights 
had been transferred  when the license agreement was signed. 
The partnership must remain at risk during the license or joint 
venture term, with no guarantee that anyone will exercise the 
option to acquire the technology. Finally, the partnership should 
not have a right to "put" the technology to anyone at the close of 
the license period. 
In order to qualify as a capital gains asset under Sec. 1221 
or 1231, the technology must be "property." Patents, patent 
applications, and some copyrights are considered property, but 
trade secrets will be considered property only if they are truly 
secret, create some competitive advantage, and are legally 
protected against unauthorized disclosure and use. Know-how 
must meet the same requirements as trade secrets or be ancillary 
to patents, applications, or trade secrets. If development is 
subcontracted out to others or if information is divulged in 
articles or speeches, then the trade secrets or know-how may not 
be truly secret and therefore  not qualify as property. For purposes 
of a patent sale, the sale of the "property" must, to satisfy Sec. 
1221, include all substantial rights, geographic and field of use. 
34 San Joaquin Fruit & Investment Co., 297 US 496 (1936) (17 AFTR 470, 36-1 USTC 
para. 9144). 
35 Karl R. Martin, 44 TC 731 (1965). 
97 
Computer software is generally protected by copyright. If 
the software is created by the taxpayer (i.e.,  the partnership),the 
copyright is ineligible for capital gains treatment. If the software 
is developed by either the sponsoring company or a third party for 
an arms-length price, it should qualify as property and be eligible 
for capital gains treatment under Sec. 1231. 
Sec. 483. Sec. 483 of the Code provides that interest be 
imputed on deferred  payments made under contracts for the sale 
of property. Since R&D royalty agreements are essentially sale 
contracts calling for long-term payments, a portion of each 
royalty payment is usually characterized as interest and is 
taxable as ordinary income. 
Sec. 1239. The sale of the technology may also raise 
issues under Sec. 1239, which disallows capital gains treatment 
on sales of depreciable property to related parties. Since patents 
(and, under some decisions, patent applications) are depreciable 
property, a sale of patented technology by the partnership to a 
related entity will result in ordinary income. For purposes of Sec. 
1239, a related entity is one in which the partnership or its 
partners own more than 80%. The Sec. 318 attribution rules apply 
in determining whether the partners and partnership own 80% or 
more of the sponsoring company. 
The sale of unpatented technology or secret formulae to 
related parties would probably not result in ordinary income treat-
ment under Sec. 1239, because these assets have an indeter-
minate useful life and are therefore  not depreciable.36 When the 
R&D partnership sells the technology to a domestic corporation, 
it can realize long-term capital gains. The corporation can then 
patent the technology and amortize its cost over the patent's life 
or a shorter period. 
Sec. 351. When the partnership owns 80% of the 
sponsoring company, the sale of unpatented technology must be 
carefully planned to prevent the transaction from being treated as 
a contribution to capital under Sec. 351. If the IRS views the sale 
as a contribution to capital, royalties later paid to the partnership 
would be treated as dividends — non-deductible to the 
corporation and ordinary income to the partners. 
Sec. 1249. Under Sec. 1249, income from the sale of a 
patent, invention, model or design by an R&D partnership to a 
controlled foreign corporation (generally, more than 50% owned, 
using Sec. 958 attribution rules) will be treated as ordinary 
income rather than capital gains. 
36 See, e.g., Lan Jen Chu, 486 F2d 696 (1st Cir. 1973) (32 AFTR2d 73-6022, 73-2 
USTC para. 9750), aff'g  58 TC 598 (1972), acq. 1978-2 CB 1; Est. of William F. Stahl, 
422 F2d 324 (7th Cir. 1971) (27 AFTR2d 71-1077, 71-1 USTC para. 9322), aff'g  in 
part and rev'g in part 52 TC 591 (1969), nonacq. 1978-2 CB 4; Bette C. Graham, N.D. 
Tex 1979 (43 AFTR2d 79-1013, 79-1 USTC para. 9274). 
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Sale of Partnership Interests 
When the sale of partnership assets does not qualify for 
capital gains treatment under Sec. 1235, the most frequently 
used alternative is the sale of the partnership interests rather 
than the technology. This approach avoids many of the problems 
previously discussed as long as the sale of the partnership inter-
ests cannot be recharacterized as a sale of assets. The holding 
period for the partnership interest starts when the investment is 
made, rather than when the technology is "reduced to practice." 
In addition, the partnership interest clearly constitutes a capital 
asset.37There are no questions as to whether a sale or exchange 
occurred, whether the technology is property, nor whether the tax 
benefit rule may be applicable. 
Under Sec. 751, however, any proceeds from the sale of 
partnership interests attributable to unrealized receivables or 
substantially appreciated inventory of the partnership will be 
taxed as ordinary income. Generally, the partnership will have un-
realized receivables only to the extent of license agreement fees 
or unrecognized income in a joint venture. 
Generally, the costs of the technology will have been de-
ducted as R&D expense, giving the partnership a zero tax basis 
for the technology. If the IRS treats the technology as inventory, 
then it will be "substantially appreciated inventory" within the 
meaning of Sec. 751. Consequently, the same issues with Secs. 
1221-23 and 1231 regarding inventory are also issues in the sale 
of partnership interests. While the holding period for partnership 
interests start when the investment is made, the partnership may 
still need to hold the technology for twelve months after  it is re-
duced to practice before the partnership interests are sold. 
The Equity Partnership 
For early-stage companies, the most popular R&D part-
nership arrangement is the "equity partnership." Under these 
arrangements, the partnership interests are converted to stock 
interests at a later date. By starting as a partnership, a company 
can pass through its early losses from expended R&D to the 
partners. The partnership can then incorporate or merge with a 
corporate entity and the partners can exchange their partnership 
interests for stock in the corporation. These stock interests can 
be sold when the company goes public or becomes involved in a 
major sale of the company's stock. Sale of the stock by the 
partners/stockholders results in capital gains. 
This approach to the realization of capital gains avoids 
many of the technical difficulties  that may arise under either Sec. 
1235 or Sec. 1221. The incorporation should be tax-free under 
Sec. 351. 
3 7 See Sec. 741. 
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When the sponsoring company gets stock in the new cor-
poration, however, the sponsoring company may appear to have 
received equity with a value greater than the property it trans-
ferred.  This "property" often consists of little more than a 
promise to provide the know-how and other skills necessary to 
manufacture and market the product. If these items are not 
considered "property" for purposes of Sec. 351, the company 
may recognize ordinary income on receipt of the stock. If the 
company receives more than 20% of the new corporation and 
does not transfer  "property" to the new corporation, the 
incorporating transaction would be taxable to the partnership. To 
achieve tax-free treatment under Sec. 351, the company should 
transfer  prototypes, cash, or equipment along with expertise, in 
exchange for the stock interest. 
Because this incorporation technique yields a tax-deduct-
ible equity investment in a corporation not achievable by buying 
stock in the corporation at the outset, it appeals to venture capi-
tal investors. The IRS may argue that the partnership should be 
disregarded because it lacks any real economic reason or sub-
stance. In many cases, the founding partners may be unable to 
demonstrate any business purpose for the interim use of a part-
nership other than providing the investors with a deductible 
equity interest in a corporation. To avoid this problem, equity 
partnerships should be designed so that the incorporation of the 
partnership does not serve as an integral part of the overall plan 
from the outset. Some recent equity partnerships provide that in-
corporation of the partnership requires an affirmative  vote by the 
general partner and a "super majority" (2/3) of the limited 
partners. This provision may introduce sufficient  uncertainty as 
to whether incorporation will, in fact, take place. 
Lump-Sum Buy-Outs 
Under many R&D contracts, the sponsoring company has 
an option to buy the technology from the partnership for a lump 
sum, payable in cash or in stock of the sponsoring company. 
Even if the lump-sum sale is structured as a capital gains transac-
tion, a lump-sum buy-out for stock may leave the partners with no 
cash to pay the capital gains tax. Accordingly, the partnership 
can often choose a combination cash-and-stock payment when 
the sponsoring company exercises its option to buy the technol-
ogy for a lump sum. 
A tax-free stock buy-out may be structured, however, 
using provisions of Sec. 351. To do this, the sponsoring company 
organizes a subsidiary after the technology is developed. The 
company transfers  to the subsidiary the prototypes, cash, and 
other assets necessary to manufacture and market the product in 
exchange for 80% of the stock. Simultaneously, the partnership 
transfers  its technology to the subsidiary in exchange for the 
100 
other 20% of the stock. By qualifying these transactions under 
Sec. 351, the partnership does not recognize gain from the 
receipt of the stock. To protect the partnership, the partners 
should be given a "put" option, allowing the partnership to put its 
stock interest to the parent corporation in exchange for parent 
company stock in the event of a public offering  or other major 
sale of the parent company's stock. Careful  drafting of the put 
will be necessary so that the put does not disqualify the transac-
tion under Sec. 351. It may also be necessary to give the parent 
company a call option on the partners' stock, so that the com-
pany can protect its interest and consolidate the subsidiary's 
earnings for financial statement purposes. 
Availability of Research and Experimentation (R&E) 
Credits 
The Committee Reports on ERTA indicate that royalty 
R&D partnerships are not eligible for the R&E tax credit under 
Sec. 44F. The mere receipt of royalties cannot be viewed as carry-
ing on a trade or business, which is required by Sec. 44F(b)(1). 
Whether the credit is available to equity partnerships is 
less clear. The IRS will probably argue that the equity partnership 
is not carrying on a trade or business until it has revenues or 
ships a product. Even if the equity partnership is considered to be 
carrying on a trade or business, Sec. 44F provides that the credits 
passed through to the partners can only be used to offset  any tax 
liability stemming from taxable income from the equity partner-
ship. In most cases, this will mean carrying the credit over to 
some future date when the partnership has net income; the 
present value of the credit may, therefore,  be of little benefit. 
Legislation has been proposed to extend the credit to 
start-up corporations and corporate joint ventures. Start-up R&D 
partnerships will probably still be excluded. 
Even in the few cases in which an R&E credit might be 
available, R&D partnerships must adhere to special rules on 
prepaid contract R&D. Where the R&D has been prepaid, only the 
portion of prepaid expenses allocable to the research performed 




TAX CONSIDERATIONS FOR 
THE SPONSORING COMPANY 
For the sponsoring company in an R&D partnership, the 
tax consequences are fairly straightforward.  The company 
should be aware of the taxation of R&D contract revenue, the 
deductibility of royalty payments, and the potential reallocations 
under Sec. 482 of the Code. 
Taxable Income 
Unlike the debt or equity funds that a company receives 
to conduct research, funds received from an R&D partnership are 
taxable. Since the partnership often prepays the R&D contract 
with no restrictions, the company that is not careful  could wind 
up using a substantial part of the proceeds to pay taxes, rather 
than to conduct research. 
The IRS has generally taken the position that prepaid 
revenue is taxable in the year of receipt. If the IRS requires a 
sponsoring R&D company to recognize prepaid R&D contract in-
come in the year of receipt, it would seem equitable to allow the 
estimated R&D costs for the project to be offset  against the 
prepaid revenue. Although some appellate courts have accepted 
this reasoning, the Tax Court has never agreed.1 
A sponsoring company should try to defer the inclusion 
of the R&D contract revenue as taxable income until the deduc-
tions for the research and development are available to offset  the 
income. The two most commonly employed techniques to 
achieve deferral  are the completed contract method and the 
Revenue Procedure 71-212 method. 
1 E.W. Schuessler, 20 F2d 722 (5th Cir. 1956) (49 AFTR 322, 56-1 USTC para. 9368), 
rev'g 24 TC 247 (1955); Pacific Grape Products Co., 219 F2d 862 (9th Cir. 1955) (47 
AFTR 214, 55-1 USTC para. 9247), rev'g and rem'g 17 TC 1097 (1952). 
2 Rev. Proc. 71-21, 1971-2 CB 549. 
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Completed Contract Method 
Under the completed contract method, the company 
reports the income and deducts costs allocable to the contract in 
the year the contract is completed (when final completion and ac-
ceptance have occurred). To use this method, Regs. Sec. 
1.451-3(a) requires a long-term contract, generally more than 12 
months. Many R&D contracts may not fall within the definition of 
a long-term contract, however, because Regs. Sec. 1.451-3(b)(1)(i) 
defines this term as "a building, installation, construction, or 
manufacturing contract which is not completed within the 
taxable year in which it is entered into." Since many R&D 
contracts are really viewed by the parties as service contracts, 
the definition may prevent the use of the completed contract 
method. For example, when an architect was basically providing 
services rather than constructing a building, he was not 
permitted to use the completed contract method to recognize his 
revenues on the contract.3 Similarly, an engineer was not allowed 
to use the method for engineering services he was providing 
because the services were not under a long-term contract, and he 
was not required to construct or build anything.4 
To minimize this problem, R&D contracts should provide 
as much support as possible for using the completed contract 
method. The contracts should specifically require the company 
to build a working prototype, or some other tangible product, 
from the R&D work and to deliver it to the partnership. Since the 
prototype would then be owned by the partnership, the partner-
ship might lose some R&D deductions for the costs necessary to 
build it. These lost deductions may not be too significant, how-
ever, when compared to the benefits the sponsoring company 
would realize from using the completed contract method. 
Revenue Procedure 71-21 
The definitional problems of the completed contract 
method can be avoided when Rev. Proc. 71-21 is used. Under Rev. 
Proc. 71-21, the inclusion of prepaid R&D in income can be de-
ferred  until the actual R&D work is performed,  but in no event 
beyond the end of the year following the year of receipt. To rely 
on the revenue procedure, the R&D contract must specify that all 
R&D is to be performed before the end of the year following the 
taxable year of receipt. 
3 Rev. Rul. 70-67, 1970-1 CB 117. 
4 Rev. Rul. 80-18, 1980-1 CB 103. 
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The actual amount of income deferred  is determined 
according to the portion of the R&D contract unperformed at the 
end of the year of receipt. For example, assume the R&D partner-
ship prepays $2 million to a calendar-year accrual basis company 
in November 1983, pursuant to a one-year contract. On December 
31, 1983, 75% of the R&D work remains unperformed.  Under Rev. 
Proc. 71-21, $500,000 of income is recognized in 1983, while $1.5 
million of income would be recognized in 1984, regardless of 
whether the contract is completed by December 1984. 
A newly-formed sponsoring company can maximize the 
deferral  available under Rev. Proc. 71-21 by electing a tax year 
which ends just before the first  prepayment is received. In this 
way, the company can defer recognition of a portion of the in-
come for almost two full years. 
The sponsoring company must maintain books and 
records to substantiate the amount deferred  at year-end. In addi-
tion, the amount included in taxable income must conform to the 
amount included in book income, or the income reported by the 
company to shareholders or to others for credit purposes. 
Deductibility of Royalty Payments 
When the sponsoring company purchases developed 
technology from the partnership, it generally expects the useful 
life of that technology to extend well beyond a year. Under con-
ventional tax accounting principles, the cost of the technology 
should be capitalized and deducted over the useful life of the 
technology. 
When the company acquires the technology in exchange 
for a royalty based on sales, the total cost must still, theoreti-
cally, be capitalized; however, the total amount may not be deter-
minable. In Associated  Patentees,  Inc.,5 the Tax Court held that 
since the total royalties that would ultimately be paid 
represented the total cost of the technology, the actual royalties 
paid during any particular period was the best indication of the 
utility (or depreciation) of that asset during the period. Thus, the 
Court permitted royalty payments to be deducted as paid or 
incurred for the period involved. 
In situations where a "cap" exists on the royalties and 
appears to be attainable before  the end of the patent's useful life, 
the IRS may argue that the royalties paid are not a reasonable 
5 Associated Patentees, Inc., 4 TC 979 (1945), acq. 1959-2 CB 3. 
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measure of the amortization. For instance, if sales projections in-
dicate that the cap will be reached within four years, the IRS may 
argue for capitalizing the expected cumulative royalties and 
amortizing that total over the patent's statutory life of seventeen 
years. Similarly, if a company must pay excess royalties to reach 
a minimum royalty level, the IRS may argue that the excess 
amounts should be capitalized. Both of these arguments may be 
difficult  to sustain, however, in view of the uncertainty of future 
sales and the real useful lives of patents. 
Allocation of Income and Deductions 
Under Sec. 482, the IRS has the authority to allocate in-
come and deductions between or among entities under common 
control if such allocation will more clearly reflect the income of 
any of the entities. In the case of an R&D partnership arrange-
ment, the IRS may attempt to allocate the partnership's R&D 
deduction to the sponsoring company or to deny the deduction 
entirely, based on a number of theories. 
If the overall arrangement is viewed as little more than an 
elaborate financing scheme rather than a genuine contract 
research project, the IRS may recharacterize the prepaid R&D as 
a loan, eliminating both the partnership's deduction and the 
company's income. Alternatively, since the partnership will 
usually not be able to manufacture or market the product 
resulting from the developed technology, the IRS may contend 
that the arrangement is actually a joint venture between the 
partnership and the sponsoring company, and recharacterize the 
prepaid R&D as a nondeductible capital contribution to the joint 
venture. In two recent cases6 the partnerships were 
recharacterized as financing transactions based upon certain 
factors in the arrangement. These factors included a legal 
obligation of the partnership to sell the developed technology, a 
general partner that provided no significant services other than 
raising capital, and a project where the partnership provided less 
than half the necessary development funds in an economic 
structure that resembled a loan. 
Overpriced research may also create problems. TEFRA 
added Sec. 6700, which imposes a penalty for "gross overvalua-
tions" in connection with tax shelters. Overvaluations of the re-
search may also lead to reallocations under Sec. 482 — the R&D 
deduction by the partnership would be disallowed to the extent 
of the overvaluation, since the payment exceeds the amounts ac-
tually required to research and develop the technology. 
6Estate of Helliwell v. Commissioner, 77 TC 1964 (1981) and Broyles v. 
Commissioner, 44 TCM 908 (1982). 
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These problems can be avoided, to some extent, if all con-
tract arrangements between the partnership and the sponsoring 
company suggest arm's-length dealings. In addition, any profit 
realized by the sponsoring company from the R&D contract 
should be reasonable. The use of an unrelated or independent 
party as the general partner should also reduce the likelihood of 
reallocations. If the sponsoring company serves as general 
partner, the company may argue that its fiduciary responsibilities 
to the limited partners prevent it from exercising too much con-
trol on behalf of the company. Because the sponsoring company 
effectively  controls both entities, however, the IRS is more likely 




The emergence of R&D partnerships in the late 1970s was 
accompanied by an increased number of SEC filings for sponsor-
ing companies. The SEC became aware that the companies re-
ceiving funds from R&D partnerships were accounting for these 
funds in many different  ways. In response, the SEC took the posi-
tion that, in the absence of evidence to the contrary, these trans-
actions were only alternative financing techniques, not true 
contract research for another entity who bore the risk of un-
successful development. Consequently, the SEC indicated that 
these transactions should be accounted for as forms of debt. Al-
though the SEC may not have viewed this approach as suitable in 
all cases, the Commission's position forced the accounting 
profession to address the issue. At the same time, R&D partner-
ship activity quickly decreased, since the availability of so-called 
"off-balance  sheet" financing, one of its major attractions, was 
virtually eliminated for public companies. 
In April 1982, the Financial Accounting Standards Board 
(FASB) issued an Exposure Draft  entitled "Research and Develop-
ment Arrangements." After  considering letters of comment in 
response to this Exposure Draft,  the FASB issued Statement  of 
Financial  Accounting  Standards  No. 68 - Research  and Develop-
ment Arrangements  (SFAS 68) in October 1982. 
SFAS 68 indicates that when research is funded by 
others, there may be an obligation, either contractually or 
otherwise, for repayment of such funding regardless of the 
project's success. In such circumstances, if the arrangement is, 
in substance, a financing technique, the sponsoring company 
must recognize its liability under the agreement in its financial 
statements in a manner similar to any commercial loan financing. 
But, if the overall arrangement is determined to be a contract to 
perform research for others, it should be accounted for 
accordingly. 
Some judgement must be used in determining whether 
the arrangement is a contract to perform research for others. The 
sponsoring company must determine the substantive nature of 
its obligation when it contracts with other parties who fund the 
research. If the company is obligated to repay (or if, based on 
surrounding circumstances, it is probable  that the company will 
repay) some of the funds provided, even if the research is unsuc-
cessful, then the company must account for this obligation as a 
liability. 
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If the sponsoring company has no liability, contractual or 
otherwise, because repayment is contingent solely upon the 
results of the project, and there is sufficient  uncertainty as to the 
project's success, the company should account for the arrange-
ment as a contract to perform R&D activities for others. To adopt 
this position, however, the economic success of the R&D cannot 
be guaranteed by the company, and the company cannot be obli-
gated to make any future payments or issue securities to the R&D 
partnership (which is sometimes true of equity partnerships). 
Determining the proper accounting treatment will be 
most difficult  when there is no contractual obligation to repay the 
partnership or to acquire the partnership's technology, but it ap-
pears likely that the sponsoring company has an intent to pur-
chase the results of the research project, even if it proves 
unsuccessful. SFAS 68 provides some examples of conditions 
that lead to the presumption that the sponsor will repay funds 
provided, including when the sponsor: (1) may want to maintain 
the ability to enter into another arrangement with the same par-
ties or similar arrangements with other parties; (2) may be forced 
to reacquire the base technology to continue conducting its 
other activities or to prevent disclosure of the technology to 
others by the partnership; or (3) may purchase the results to fulfill 
a perceived moral obligation. Similarly, a sponsoring company 
may be the general partner and, because of a conflict of interest, 
may feel compelled to exercise an option to buy the technology. 
Even though written agreements or contracts may not require 
repayment of the R&D funds received, surrounding conditions 
might indicate that the sponsor is likely to bear the risk of failure 
of the R&D effort.  Accordingly, the individual facts and circum-
stances of each situation must be evaluated. 
To persuade potential investors, companies sometimes 
describe the R&D project as "Big D" (development) and "Litt le R" 
(research) to suggest a lower degree of risk. SFAS 68 states that if 
the sponsoring company has essentially completed the project 
before entering into the arrangement with the R&D partnership, 
there is a presumption that the company will buy out the partner-
ship. Applying the phrase "essentially completed" to high tech-
nology contracts may be very difficult  for accountants who lack 
substantial engineering or other technological knowledge. 
In those situations where the sponsoring company serves 
as the general partner and contributes cash to the partnership, 
the problem of accounting for that investment must be ad-
dressed. In an arrangement that has been determined to be a con-
tract to perform research for others under the provisions of SFAS 
68, the equity method generally should be used, with the invest-
ment reduced as the partnership incurs development expense. In 
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certain situations where the sponsoring company is able to con-
trol the financial and operating policies of the partnership, con-
solidation of the partnership with the sponsoring company may 
be appropriate. Control of the partnership may exist even if the 
general partner has an interest of less than 50%. 
SFAS 68 does not address the accounting treatment for 
buy-out arrangements of the successfully developed project. The 
appropriate treatment involves an assessment of the specific 
facts in each situation. The arrangement may contemplate that 
the sponsor will eventually acquire the successfully developed 
technology for cash, stock or a combination of cash and stock. 
An acquisition for cash may result in the sponsor recording an 
asset and amortizing that asset over the future periods benefited. 
However, there are numerous accounting issues that should be 
considered. One such issue involves R&D arrangements that 
permit the partnership to receive payment from the sponsor for 
the successfully developed project in the form of sponsor 
company's stock. The FASB, in Technical Bulletin 84-1 (dated 
March 15,1984), states that a company which acquires the results 
of an R&D arrangement in exchange for stock should record the 
stock at (1) the stock's fair  value as of the date the company 
exercises its right to acquire the technology or (2) the fair  value of 
the technology, whichever is more clearly evident. The fair  value 
of the stock will normally be more clearly evident. In those 
situations where the value of the sponsoring company's stock 
has appreciated such that the stock value far exceeds the 
alternative cash amount, this treatment may result in the 
recording of an asset much larger than originally contemplated. 
The large asset may raise a further  question as to whether the 
recorded amount will be recoverable. 
Other complexities are introduced when the purchase of 
the developed technology by the sponsor is negotiated before 
the development is successfully completed. In this regard, GAAP 
precludes capitalization of the costs of services performed by 
others in connection with the research and development 
activities of the sponsor, including research and development 
conducted by others on behalf of the sponsor. However, the 
costs of intangibles that are purchased from others for use in 
research and development activities and that have alternative 
future uses (in research and development projects or otherwise) 
are capitalizable costs. 
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Most partnership arrangements are set up with the tax im-
plications firmly in mind. Because the requirements of SFAS 68 
are similar to the tax requirements for contract treatment, the 
sponsoring company may be able to account for the R&D partner-
ship arrangement as a research contract if, for tax purposes, such 
an arrangement qualified to be treated as a contract to perform 
R&D for others. 
Another accounting issue arises when the sponsor lends 
additional funds to the partnership to complete the project. The 
appropriate accounting treatment will depend on the repayment 
terms. In most situations, repayment is contingent on successful 
development (e.g., the amount loaned is offset  against future 
royalties payable to the partnership), and the sponsor would 
account for the loan as R&D expense. 
Pure equity partnership arrangements designed to launch 
new companies present other accounting problems. The initial 
issue is: Are the partnership and sponsor really separate entities, 
or are the limited partners merely investors in the sponsor? While 
the legal form may indicate separate entities, the substance of 
the arrangement may dictate that the sponsor and the 
partnership be combined for accounting purposes. Other issues 
arise when the partnership incorporates or when the partnership 
and the sponsor combine. Generally, when the partnership and 
the sponsor have been combined for financial accounting 
purposes and a legal combination of the entities occurs, such a 
combination will be treated similar to a pooling of interests. But, 
again, the specific circumstances surrounding each situation 
must first  be evaluated. 
Many of these accounting issues have not been fully 
resolved by the accounting profession, and will ultimately be 
addressed by interpretation of existing accounting rules and 
establishment of new accounting standards. In the meantime, 
those considering the formation of R&D partnerships should con-
sult accounting professionals as to the potential accounting con-
sequences of any contemplated arrangement. 
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Deloitte Haskins & Sells has created this guidebook as an industry service. 
If you would like additional copies, please contact our Executive Office  or 
any of our 423 practice offices  worldwide. 
Our U.S. offices  are listed here for your convenience. 
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